Methods for in situ monitoring and control of defect formation or healing

Information

  • Patent Grant
  • 10203295
  • Patent Number
    10,203,295
  • Date Filed
    Thursday, April 14, 2016
    8 years ago
  • Date Issued
    Tuesday, February 12, 2019
    5 years ago
Abstract
Production of perforated two-dimensional materials with holes of a desired size range, a narrow size distribution, and a high and uniform density remains a challenge, at least partially, due to physical and chemical inconsistencies from sheet-to-sheet of the two-dimensional material and surface contamination. This disclosure describes methods for monitoring and adjusting perforation or healing conditions in real-time to address inter- and intra-sheet variability. In situ or substantially simultaneous feedback on defect production or healing may be provided either locally or globally on a graphene or other two-dimensional sheet. The feedback data can be used to adjust perforation or healing parameters, such as the total dose or efficacy of the perforating radiation, to achieve the desired defect state.
Description
BACKGROUND

Graphene represents a form of carbon in which the carbon atoms reside within a single atomically thin sheet or a few layered sheets (e.g., about 20 or less) of fused six-membered rings forming an extended planar lattice. In its various forms, graphene has garnered widespread interest for use in a number of applications, primarily due to its favorable combination of high electrical and thermal conductivity values, good in-plane mechanical strength, and unique optical and electronic properties. Of particular interest to industry are large-area graphene films for applications such as, for example, special barrier layers, coatings, large area conductive elements (e.g., RF radiators or antennas), integrated circuits, transparent electrodes, solar cells, gas barriers, flexible electronics and the like.


Some envisioned applications for graphene and other two-dimensional materials are predicated upon introducing defects, such as forming a plurality of nanometer-scale holes in the planar structure. For example, the hole density of perforated graphene can be used to tune the electrical conductivity of this nanomaterial and in some instances can be used to adjust its electronic band structure. Filtration applications are another area where perforated graphene and other perforated two-dimensional materials have generated considerable interest. Due to the atomic-level thinness of graphene and other two-dimensional materials, it is possible to achieve high fluid throughput fluxes during filtration processes.


A number of processes are known for perforating and/or defecting graphene and other two-dimensional materials (e.g., ion bombardment, oxidation, nanoparticle bombardment, etc.). Likewise, a number of techniques for healing holes, that are too large for a given application, in graphene and other two-dimensional materials have been disclosed (see, for example, US patent application filed herewith, entitled METHOD FOR MAKING TWO-DIMENSIONAL MATERIALS AND COMPOSITE MEMBRANES THEREOF HAVING SIZE-SELECTIVE PERFORATIONS, U.S. Pat No. 15/099,482 incorporated herein in its entirety). However, production of holes with a desired size range, a narrow size distribution, and a high and uniform hole density remains a challenge, at least partially, due to small physical and chemical inconsistencies from sheet-to-sheet of the two-dimensional material (e.g. layers, intrinsic or native defects, strain, electron distribution and crystallinity) and surface contamination. Currently, there is no way to monitor and adjust perforation or healing conditions in real-time. Instead, samples are perforated or healed, then tested by a separate process, and perforation or healing parameters are adjusted and applied to a new sheet of material, which inevitably possesses chemical and physical variations that cause it to respond differently to the new conditions. For example, contamination from sample to sample may vary, and needs to be accounted for. Typically to validate a perforation process, graphene needs to be transferred simultaneously to multiple TEM grids and to a desired support substrate. The TEM grids are then exposed to various different treatments. These must then be individually loaded into an STEM and imaged to determine the perforation results. If one of the conditions turns out to be appropriate, the the graphene on the support substrate is then subjected to the same treatment.


In view of the foregoing, methods that monitor and adjust for inter- and intra-sheet variability during perforation or healing of graphene and other two-dimensional materials would be of considerable interest in the art. In particular, methods for real-time, in situ monitoring of defect formation or healing would be of considerable interest in the art. For example, monitoring of defect formation or healing for suspended graphene would be of interest. The present disclosure satisfies the foregoing needs and provides related advantages as well.


SUMMARY

This disclosure provides methods for monitoring a variety of perforation and healing procedures via monitoring schemes that provide real-time feedback, while defects are being produced or healed. The invention describes several detection mechanisms that provide in situ or substantially simultaneous feedback on defect production or healing either locally or globally for a graphene or two-dimensional sheet. The feedback data can be used to adjust perforation or healing parameters, such as the total dose or efficacy of the perforating radiation, to achieve the desired defect state. This method advantageously accounts for inter- and intra-sheet chemical and physical variability. Variability may arise from varying substrate/graphene interaction. For example, variability may arise from nanoparticles (NPs) perforating graphene differently in some instances, such as when the area of the substrate pore that the NP spans changes. This method advantageously accounts for this variance in the perforation system, and monitors, for example, defects created by NPs perforating the substrate.


In an aspect, a method for monitoring defect formation or healing comprises: exposing a surface of a material to incident radiation; detecting scattered, emitted or transmitted radiation from at least a portion of the material exposed to the incident radiation; and generating data indicative of defect formation or healing, wherein the method is performed in situ and the data indicative of defect formation or healing provides a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof. As described herein the incident radiation, and the scattered, emitted or transmitted radiation may be any one or more of electromagnetic radiation, electrons, ions, nanoparticles, or plasma. In an embodiment, incident radiation is processing radiaton, such as perforating or healing radiation or interrogating radiation. The incident radiation may also be both processing radiation and interrogating radiation. As described herein, processing radiation performs a process on the material when incident thereon.


In an embodiment, the step of generating data indicative of defect formation comprises determining secondary electron yield.


In an embodiment, the step of exposing the surface of the material to incident radiation produces a plurality of defects in the material.


In an embodiment, the step of detecting radiation or particles comprises: (i) performing secondary ion mass spectroscopy; (ii) performing Raman spectroscopy; (iii) performing residual gas analysis on particles being removed from the material; (iv) detecting back scattered radiation or particles; (v) detecting Auger electrons; (vi) performing scanning probe microscopy; (vii) performing scanning tunneling microscopy; (viii) performing atomic force microscopy; (ix) performing X-ray photoelectron spectroscopy; (x) performing transmission electron microscopy; (xi) detecting nanoparticles on one or more microbalances or Faraday cups positioned behind the material; (xii) performing small angle electron diffraction; (xiii) detecting nanoparticles on a surface positioned behind the material using surface enhanced Raman scattering (SERS); (xiv) detecting secondary electrons; (xv) detecting transmitted electron or ions; or (xvi) performing a combination of two or more of (i)-(xv). In an embodiment, the back scattered radiation or particles are selected from the group consisting of electrons, protons and helium. In an embodiment, scattered radiation or particles are selected from the group consisting of electrons, protons, helium, gallium, neon, argon, xenon, or ions.


In an embodiment, the steps of exposing and detecting occur simultaneously.


In an embodiment, the incident radiation and the scattered, emitted or transmitted radiation are the same type of radiation or different types of radiation. In an embodiment, the scattered, emitted or transmitted radiation results from the incident radiation or an additional source of interrogating radiation.


In an embodiment, the scattered, emitted or transmitted radiation from the material is collected from a bulk portion of the surface having an area between 1 μm2 and 1000 cm2. In an embodiment, the scattered, emitted or transmitted radiation from the material is collected from a local portion of the surface having an area between 100 nm2 and 10 mm2.


In an embodiment, the scattered, emitted or transmitted radiation is continuously collected. In an alternate embodiment, the incident radiation is pulsed and the scattered, emitted or transmitted radiation is collected only when the incident radiation is off. As noted above, the incident radiation, and the scattered, emitted or transmitted radiation may be any one or more of electromagnetic radiation, electrons, ions, nanoparticles, or plasma.


In an embodiment the emitted radiation is secondary electrons. The secondary electrons could be generated by electrons or ions, for example.


Methods for monitoring defect formation or healing via gas permeation are also contemplated. For example, in an aspect, a method for monitoring defect formation or healing comprises: exposing a surface of a material to incident radiation; detecting movement of an analyte through defects in the material; and generating data indicative of defect formation or healing, wherein the method is performed in situ and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, a maximum size of the defects, a number of pores, or combinations thereof.


In an embodiment, the step of detecting movement of the analyte through the defects in the material comprises one or more of: (i) determining the presence or absence of the analyte at a detector; (ii) quantifying the analyte; (iii) identifying a composition, mass, average radius, charge or size of the analyte; (iv) determining a rate of movement of the analyte through the defects in the material; or (v) a combination of two or more of (i)-(iv). In an embodiment, the analyte is a gas selected from the group consisting of hydrogen, helium, oxygen, nitrogen, xenon, neon, argon, SF6, H2O, CxH2x where x is 1 to 4, and combinations thereof. In an embodiment, the analyte is a plasma. In an embodiment, the incident radiation is a plasma, potentially capable of perforating or modifying the two-dimensional material, and the analyte is one or more species of the plasma. For example, the one or more species of the plasma may be a charged species.


Methods for monitoring defect formation or healing via electrical biasing are also contemplated. For example, in an aspect, a method for monitoring defect formation or healing, comprises: exposing a surface of the material to incident radiation; applying an electrical bias to the material; measuring electrical conductivity through a conductive probe in electrical contact with the material; and generating data indicative of defect formation or healing, wherein the method is performed in situ and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof. In an embodiment, a conductive probe is a conductive grid or a local probe. In an embodiment, defect density and electrical conductivity are inversely related such that an increase in defect density is observed as a decrease in electrical conductivity. In an embodiment the electrical conductivity of the material changes as a result of the defects. Further, defects in graphene other than holes may be beneficial for being detected based on electronic properties in a number of applications. For example, disrupting the graphene lattice and making 5 and 7 member rings, instead of the typical 6 member rings, can beneficially change the electronic properties of graphene. Likewise, doping of the graphene can also be beneficial, for example substituting boron, nitrogen, or silicon atoms in graphene can change the electrical properties sufficiently to be detected.


Methods for monitoring defect formation or healing via heating are also contemplated. For example, in an aspect, a method for monitoring defect formation or healing, comprises: exposing a surface of a material to incident radiation; heating the material; subsequently measuring temperature of the surface of the material; and generating data indicative of defect formation or healing, wherein the method is performed in situ and the data indicative of defect formation or healing provides a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof. In an embodiment, the step of heating the material comprises applying a potential to the two-dimensional material to induce joule heating. In an embodiment, defect density and thermal conductivity are inversely related such that an increase in defect density is observed as a decrease in thermal conductivity.


In an embodiment, the incident radiation is a particle beam. In an embodiment for monitoring a bulk portion of a material, the particle beam produces a spot on the surface of the material, the spot having an area between 1 μm2 and 100 cm2, or between 10 μm2 and 10 cm2. In an embodiment for monitoring a local portion of a material, the particle beam is a microbeam that produces a spot on the surface of the material, the spot having an area between 1 nm2 and 1 mm2, or between 10 nm2 and 10 μm2.


In an embodiment, the particle beam is an ion beam, where the ion beam has an ion energy of at least 20 eV, or at least 50 eV, or at least 100 eV. For example, the ion beam may have an ion energy selected from the range of 20 eV to 10 keV, or 20 eV to 1 keV, or 50 eV to 1 keV, or 100 eV to 1 keV. In an embodiment, the ion beam has a flux selected from the range of 10 pA/mm2 to 1 μA/mm2, or 10 nA/mm2 to 10 mA/mm2, or 50 nA/mm2 to 5 mA/mm2. In an embodiment, the surface of the material is exposed to an ion dose ranging from 1×1011 ions/cm2 to 1×1020 ions/cm2, or from 1×1012 ions/cm2 to 1×1018 ions/cm2, or from 1×1012 ions/cm2 to 1×1015 ions/cm2. In an embodiment, the ion beam comprises ions selected from the group consisting of He+, Xe+, Ne+, Ar+, Cs+, Bi3+, Au+, Au3+ and combinations thereof. In an embodiment, the ion beam comprises organic or organometallic ions having a molecular mass from 90 to 200. In an embodiment, the ion beam comprises ions selected from the group consisting of tropylium ions, ferrocenium ions and combinations thereof.


In an embodiment, the particle beam is an electron beam. For example, the electron beam has an energy of at least 10 eV, or at least 100 eV, or at least 1 keV. In an embodiment, the electron beam may be interrogating radiation having an energy selected from the range of 10 eV to 40 keV, or 100 eV to 20 keV, or 1 keV to 10 keV. In an embodiment, the electron beam may be perforating radiation having an energy greater than or equal to 84 keV in the case of pristine graphene, or may be lower when the graphene is not pristine, such as when the graphence has carbon atoms without 3 sp2 bonds.


In an embodiment, the particle beam is a nanoparticle beam. For example, the nanoparticle beam has an energy of at least 1 keV per nanoparticle, or at least 2 keV per nanoparticle, or at least 10 keV per nanoparticle. In an embodiment, the nanoparticle beam has an energy selected from the range of 2 keV to 500 keV per nanoparticle, or 5 keV to 300 keV per nanoparticle, or 10 keV to 200 keV per nanoparticle. In an embodiment, the nanoparticle beam has a flux selected from the range of 1.6×105 nanoparticles/s·cm2 to 1×1015 nanoparticles/s·cm2, or 1×106 nanoparticles/s·cm2 to 1×1012 nanoparticles/s·cm2, or 1×107 nanoparticles/s·cm2 to 1×1010 nanoparticles/s·cm2. In an embodiment, the surface of the material is exposed to a nanoparticle dose ranging from 1×108 nanoparticles/cm2 to 1×1012 nanoparticles/cm2, or from 1×109 nanoparticles/cm2 to 1×1011 nanoparticles/cm2. In an embodiment, the nanoparticle beam comprises atoms or molecules selected from the group consisting of metal nanoparticles, carbon nanoparticles, gas clusters, core shell nanoparticles and combinations thereof. In an embodiment, the nanoparticle beam comprises atoms or molecules having a molecular mass from 100 to 4,000,000, or from 190 to 2,000,000.


In an embodiment, the material is a two-dimensional material. For example, the two-dimensional material may be a single atomic layer thick. In an embodiment, the two-dimensional material has a thickness less than or equal to 100 Angstroms. In an embodiment, the two-dimensional material is selected from the group consisting of a graphene or graphene-based film, a transition metal dichalcogenide, α-boron nitride, silicene, germanene, and combinations thereof. In an embodiment, the two-dimensional material is disposed on or supported by a three-dimensional material. In an embodiment, the material comprises a stack of two or more sheets of two-dimensional material, wherein each sheet is a single atomic layer thick. In an embodiment, the size of the holes or defects in the two-dimensional material ranges from 1-50 nm, 1-30 nm, 1-20 nm, 1-10 nm or 3-10 nm. In an embodiment, the two-dimensional material is graphene or a graphene-based material.


In an embodiment, the defects are pores extending throughout a thickness of the material. For example, the pores may have an average characteristic dimension less than or equal to 1 nm. In an embodiment, the pores have an average characteristic dimension ranging from 0.3 nm to 100 nm, or from 0.5 nm to 10 nm. In an embodiment, in situ or substantially simultaneous feedback on defect production or healing may be provided either locally or globally on a graphene or other two-dimensional sheet. The feedback data can be used to adjust perforation or healing parameters, such as the total dose or efficacy of the perforating radiation, to achieve the desired defect state.


In an embodiment, a method of monitoring further comprises comparing the data indicative of defect formation or healing to a threshold range for the data; and adjusting an energy or amount of the incident radiation if the data is outside of the threshold range. In this case, the flux, energy, sample temperature, background gas pressure could be changed, as well as the incidence angle.


In an embodiment, in situ or substantially simultaneous feedback on defect production or healing may be provided either locally or globally on a graphene or other two-dimensional sheet. The feedback data can be used to adjust perforation or healing parameters, such as the total dose or efficacy of the perforating radiation, to achieve the desired defect state.


In an embodiment, a method of monitoring defect formation or healing further comprises translating the material being defected or healed along a processing stage at a rate dependent upon a rate of defect formation or healing. The rate would depend on flux and energy of the incident radiation. In an embodiment, the fluence delivered to the material may be controlled by the rate at which the material is translated relative to the irradiating beam. In an embodiment, the ions from irradiating beam may be stopped from impinging on the surface of the sample by adjusting the bias on the material up to the ion accelerating voltage to stop the ions.


The foregoing has outlined rather broadly the features of the present disclosure in order that the detailed description that follows can be better understood. Additional features and advantages of the disclosure will be described hereafter. These and other advantages and features will become more apparent from the following description.





BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present disclosure, and the advantages thereof, reference is now made to the following descriptions to be taken in conjunction with the accompanying drawings describing specific embodiments of the disclosure.



FIG. 1 is a schematic of graphene, which may be a two-dimensional material monitored by methods herein.



FIG. 2 shows a flowchart for a method for monitoring defect formation or healing via detection of scattered, emitted or transmitted radiation or particles, according to an embodiment of the present invention.



FIG. 3 shows a flowchart for a method for monitoring defect formation or healing via detection of movement of an analyte, according to an embodiment of the present invention.



FIG. 4 shows a flowchart for a method for monitoring defect formation or healing via measurement of electrical conductivity, according to an embodiment of the present invention.



FIG. 5 shows a flowchart for a method for monitoring defect formation or healing via Joule heating and temperature measurement, according to an embodiment of the present invention.



FIGS. 6A and 6B show schematics of exemplary systems for monitoring defect formation or healing, according to the embodiments of the present invention.





DETAILED DESCRIPTION

Graphene has garnered widespread interest for use in a number of applications due to its favorable mechanical and electronic properties, as well as its chemical inertness. Graphene represents an atomically thin two-dimensional layer of carbon in which the carbon atoms reside as closely spaced atoms at regular lattice positions. The regular lattice positions can have a plurality of defects present therein, which can occur natively or be intentionally introduced to the graphene basal plane. Such defects will also be equivalently referred to herein as “apertures,” “perforations” or “holes.” The term “perforated graphene” is used herein to denote a graphene sheet with defects in its basal plane, regardless of whether the defects are natively present or intentionally produced. Aside from such apertures, graphene and other two-dimensional materials can represent an impermeable layer to many substances. Therefore, when sized properly, the apertures in the impermeable layer of such materials can be useful for filtration and sequestration, for example.


Two-dimensional materials are, most generally, those which are atomically thin, with thickness ranging from single-layer sub-nanometer thickness to a few nanometers, and which generally have a high surface area. Two-dimensional materials include metal chalogenides (e.g., transition metal dichalogenides), transition metal oxides, hexagonal boron nitride, graphene, silicene and germanene (see: Xu et al. (2013) “Graphene-like Two-Dimensional Materials) Chemical Reviews 113:3766-3798). Graphene represents a form of carbon in which the carbon atoms reside within a single atomically thin sheet or few layered sheets (e.g., about 20 or less) of covalently bound carbon atoms forming an extended sp2-hybridized planar lattice. In its various forms, graphene has garnered widespread interest for use in a number of applications, primarily due to its favorable combination of high electrical and thermal conductivity values, good in-plane mechanical strength, and unique optical and electronic properties. Other two-dimensional materials having a thickness of a few nanometers or less and an extended substantially planar lattice are also of interest for various applications. In an embodiment, a two dimensional material has a thickness of 0.3 to 1.2 nm. In other embodiments, a two dimensional material has a thickness of 0.3 to 3 nm.


In various embodiments, the two-dimensional material comprises a sheet of a graphene-based material. In an embodiment, the sheet of graphene-based material is a sheet of single- or multi-layer graphene or a sheet comprising a plurality of interconnected single- or multi-layer graphene domains. In embodiments, the multilayer graphene domains have 2 to 5 layers or 2 to 10 layers. In an embodiment, the layer comprising the sheet of graphene-based material further comprises non-graphenic carbon-based material located on the surface of the sheet of graphene-based material. In an embodiment, the amount of non-graphenic carbon-based material is less than the amount of graphene. In embodiments, the amount of graphene in the graphene-based material is from 60% to 95% or from 75% to 100%. In an embodiment, the amount of graphene in the graphene-based material is measured as an atomic percentage.


In embodiments, the characteristic size of the perforations of a perforated graphene, graphene-based or two-dimensional material is from 0.3 to 10 nm, from 1 to 10 nm, from 5 to 10 nm, from 5 to 20 nm, from 10 nm to 50 nm, from 50 nm to 100 nm, from 50 nm to 150 nm, from 100 nm to 200 nm, or from 100 nm to 500 nm. In an embodiment, the average pore size of a perforated graphene, graphene-based or two-dimensional material is within the specified range. In embodiments, 70% to 99%, 80% to 99%, 85% to 99% or 90 to 99% of the perforations in a sheet or layer fall within a specified range, but other pores fall outside the specified range.


The technique used for forming the graphene or graphene-based material in the embodiments described herein is not believed to be particularly limited. For example, in some embodiments CVD graphene or graphene-based material can be used. In various embodiments, the CVD graphene or graphene-based material can be liberated from its growth substrate (e.g., Cu) and transferred to a polymer backing, or may be transferred to a porous substrate.


Likewise, the techniques for introducing perforations to the graphene or graphene-based material are not believed to be particularly limited, other than being chosen to produce perforations within a desired size range. Perforations are sized as described herein to provide desired selective permeability of a species (atom, molecule, protein, virus, cell, etc.) for a given application. Selective permeability relates to the propensity of a porous material or a perforated two-dimensional material to allow passage (or transport) of one or more species more readily or faster than other species, or to block the other species from passage. Selective permeability allows separation of species which exhibit different passage or transport rates. In two-dimensional materials selective permeability correlates to the dimension or size (e.g., diameter) of apertures and the relative effective size of the species. Selective permeability of the perforations in two-dimensional materials, such as graphene-based materials, can also depend on functionalization of perforations (if any) and the specific species that are to be separated or blocked. Separation of two or more species in a mixture includes a change in the ratio(s) (weight or molar ratio) of the two or more species in the mixture after passage of the mixture through a perforated two-dimensional material.


Graphene-based materials include, but are not limited to, single layer graphene, multilayer graphene or interconnected single or multilayer graphene domains and combinations thereof. In an embodiment, graphene-based materials also include materials which have been formed by stacking single layer or multilayer graphene sheets. In embodiments, multilayer graphene includes 2 to 20 layers, 2 to 10 layers or 2 to 5 layers. In embodiments, graphene is the dominant material in a graphene-based material. For example, a graphene-based material comprises at least 30% graphene, or at least 40% graphene, or at least 50% graphene, or at least 60% graphene, or at least 70% graphene, or at least 80% graphene, or at least 90% graphene, or at least 95% graphene. In embodiments, a graphene-based material comprises a range of graphene selected from 30% to 95%, from 40% to 80%, from 50% to 70%, from 60% to 95% or from 75% to 100%. In an embodiment, the amount of graphene in the graphene-based material is measured as an atomic percentage.


Graphene represents a form of carbon in which the carbon atoms reside within a single atomically thin sheet or a few layered sheets (e.g., about 20 or less) of fused six-membered rings forming an extended sp2-hybridized carbon planar lattice. Graphene-based materials include, but are not limited to, single layer graphene, multilayer graphene or interconnected single or multilayer graphene domains and combinations thereof. In embodiments, multilayer graphene includes 2 to 25 layers, 2 to 20 layers, 2 to 10 layers or 2 to 5 layers. In an embodiment, layers of multilayered graphene are stacked, but are less ordered in the z direction (perpendicular to the basal plane) than a thin graphite crystal.


In an embodiment, graphene-based materials also include materials which have been formed by stacking single or multilayer graphene sheets. Multi-layered graphene as referred to herein includes multiple sheets of graphene formed by layering as-synthesized sheets on a substrate. In an embodiment, layers of as-synthesized sheets of graphene which have been stacked in this fashion are less ordered in the z direction than an as-synthesized multilayer graphene sheet. Suitable as-synthesized sheets include sheets of single layer graphene (SLG), sheets of bi-layer graphene (BLG) or sheets of few layer graphene (FLG graphene, for example up to 5 layers of graphene). For example, a sheet of single layer graphene (SLG) is layered via float-down on top of a substrate. Another sheet of the SLG is then floated down on the already prepared SLG-substrate stack. This would now be 2 layers of “as-synthesized” SLG on top of the substrate. This can be extended to few layer graphene (FLG) or a mixture of SLG and FLG; and can be achieved through transfer methods known to the art. For example, a polymer transfer method can be used to assemble the stack of polymer layers. In some instances a number of layers is intended to refer to that number of separate layers of transferred graphene. In cases where a layer of transferred graphene can have a range of graphene layers (e.g. some regions of the layer are SLG and others are BLG or FLG), the stack has a range of graphene layers. For example, if 5 layers of transferred graphene each have 1 to 5 layers, then regions where the 5 sheets line up with 5 layers, effectively have 25 layers of graphene at that position. Depending on the perforation conditions, the thicker regions of the stack may not perforate. In embodiments, layering of different sheets of graphene results in a desirable membrane for filtration and separation applications.


In an embodiment, a sheet of graphene-based material is a sheet of single or multilayer graphene or a sheet comprising a plurality of interconnected single or multilayer graphene domains. In embodiments, the multilayer graphene domains have 2 to 5 layers or 2 to 10 layers. As used herein, a “domain” refers to a region of a material where atoms are uniformly ordered into a crystal lattice. A domain is uniform within its boundaries, but different from a neighboring region. For example, a single crystalline material has a single domain of ordered atoms. In an embodiment, at least some of the graphene domains are nanocrystals, having domain size from 1 to 100 nm or 10 to 100 nm. In an embodiment, at least some of the graphene domains have a domain size from 100 nm to 1 micron, or from 200 nm to 800 nm, or from 300 nm to 500 nm. “Grain boundaries” formed by crystallographic defects at edges of each domain differentiate between neighboring crystal lattices. In some embodiments, a first crystal lattice may be rotated relative to a second crystal lattice, by rotation about an axis perpendicular to the plane of a sheet, such that the two lattices differ in “crystal lattice orientation.”


In an embodiment, the sheet of graphene-based material comprises a sheet of single layer or multilayer graphene or a combination thereof. In an embodiment, the sheet of graphene-based material is a sheet of single layer or multilayer graphene or a combination thereof. In another embodiment, the sheet of graphene-based material is a sheet comprising a plurality of interconnected single or multilayer graphene domains. In an embodiment, the interconnected domains are covalently bonded together to form the sheet. When the domains in a sheet differ in crystal lattice orientation, the sheet is polycrystalline.


In embodiments, the thickness of the sheet of graphene-based material is from 0.34 to 10 nm, from 0.34 to 5 nm, or from 0.34 to 3 nm. In an embodiment, a sheet of graphene-based material comprises intrinsic or native defects. Intrinsic or native defects are those resulting from preparation of the graphene-based material in contrast to perforations which are selectively or intentionally introduced into a sheet of graphene-based material or a sheet of graphene. Such intrinsic or native defects may include, but are not limited to, lattice anomalies, pores, tears, cracks or wrinkles. Lattice anomalies can include, but are not limited to, carbon rings with other than 6 members (e.g. 5, 7 or 9 membered rings), vacancies, interstitial defects (including incorporation of non-carbon atoms in the lattice), and grain boundaries.


In an embodiment, the layer comprising the sheet of graphene-based material further comprises non-graphenic carbon-based material located on the surface of the sheet of graphene-based material. In an embodiment, the non-graphenic carbon-based material does not possess long range order and may be classified as amorphous. In embodiments, the non-graphenic carbon-based material further comprises elements other than carbon and/or hydrocarbons. Non-carbon elements which may be incorporated in the non-graphenic carbon include, but are not limited to, hydrogen, oxygen, silicon, copper and iron. In embodiments, the non-graphenic carbon-based material comprises hydrocarbons. In embodiments, carbon is the dominant material in non-graphenic carbon-based material. For example, a non-graphenic carbon-based material comprises at least 30% (weight %) carbon, or at least 40% carbon, or at least 50% carbon, or at least 60% carbon, or at least 70% carbon, or at least 80% carbon, or at least 90% carbon, or at least 95% carbon. In embodiments, a non-graphenic carbon-based material comprises a range of carbon selected from 30% to 95%, or from 40% to 80%, or from 50% to 70%. In an embodiment, the amount of carbon in the non-graphenic carbon-based material is measured as an atomic percentage.


Such nanomaterials in which pores are intentionally created will be referred to herein as “perforated graphene,” “perforated graphene-based materials” or “perforated two-dimensional materials.” The present disclosure is also directed, in part, to perforated graphene, perforated graphene-based materials and other perforated two-dimensional materials containing a plurality of holes of size (or size range) appropriate for a given application. The size distribution of holes may be narrow, e.g., limited to a 1-10% deviation in size or a 1-20% deviation in size. In an embodiment, the characteristic dimension of the holes is selected for the application. For circular holes, the characteristic dimension is the diameter of the hole. In embodiments relevant to non-circular pores, the characteristic dimension can be taken as the largest distance spanning the hole, the smallest distance spanning the hole, the average of the largest and smallest distance spanning the hole, or an equivalent diameter based on the in-plane area of the pore. As used herein, perforated graphene-based materials include materials in which non-carbon atoms have been incorporated at the edges of the pores.


In various embodiments, the two-dimensional material comprises graphene, molybdenum disulfide, or hexagonal boron nitride. In more particular embodiments, the two-dimensional material can be graphene. Graphene according to the embodiments of the present disclosure can include single-layer graphene, multi-layer graphene, or any combination thereof. Other nanomaterials having an extended two-dimensional molecular structure can also constitute the two-dimensional material in the various embodiments of the present disclosure. For example, molybdenum disulfide is a representative chalcogenide having a two-dimensional molecular structure, and other various chalcogenides can constitute the two-dimensional material in the embodiments of the present disclosure. Choice of a suitable two-dimensional material for a particular application can be determined by a number of factors, including the chemical and physical environment into which the graphene or other two-dimensional material is to be terminally deployed.


The process of forming holes in graphene and other two-dimensional materials will be referred to herein as “perforation,” and such nanomaterials will be referred to herein as being “perforated.” In a graphene sheet an interstitial aperture is formed by each six-carbon atom ring structure in the sheet and this interstitial aperture is less than one nanometer across. In particular, this interstitial aperture is believed to be about 0.3 nanometers across its longest dimension (the center to center distance between carbon atoms being about 0.28 nm and the aperture being somewhat smaller than this distance). Perforation of sheets comprising two-dimensional network structures typically refers to formation of holes larger than the interstitial apertures in the network structure.


Due to the atomic-level thinness of graphene and other two-dimensional materials, it may be possible to achieve high fluid throughput fluxes during separation or filtration processes, even with holes that are in the ranges of 1-200 nm, 1-100 nm, 1-50 nm, or 1-20 nm.


Chemical techniques can be used to create holes in graphene and other two-dimensional materials. Exposure of graphene or another two-dimensional material to ozone or atmospheric pressure plasma (e.g., an oxygen/argon or nitrogen/argon plasma) can effect perforation. Other techniques, such as ion bombardment, can also be used to remove matter from the planar structure of two-dimensional materials in order to create holes. All such methods can be applied for preparation of perforated two-dimensional materials for use herein dependent upon the hole sizes or range of hole sizes desired for a given application.


In various embodiments of the present disclosure, the holes produced in the graphene or other two-dimensional material can range from about 0.3 nm to about 50 nm in size. In a more specific embodiment, hole sizes can range from 1 nm to 50 nm. In a more specific embodiment, hole sizes can range from 1 nm to 10 nm. In a more specific embodiment, hole sizes can range from 5 nm to 10 nm. In a more specific embodiment, hole sizes can range from 1 nm to 5 nm. In a more specific embodiment, the holes can range from about 0.5 nm to about 2.5 nm in size. In an additional embodiment, the hole size is from 0.3 to 0.5 nm. In a further embodiment, the hole size is from 0.5 to 10 nm. In an additional embodiment, the hole size is from 5 nm to 20 nm. In a further embodiment, the hole size is from 0.7 nm to 1.2 nm. In an additional embodiment, the hole size is from 10 nm to 50 nm. In embodiments where larger hole sizes are preferred, the hole size is from 50 nm to 100 nm, from 50 nm to 150 nm, or from 100 nm to 200 nm.


In general, the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art. The following definitions are provided to clarify their specific use in the context of the invention.


As used herein, the term “two-dimensional material” will refer to any extended planar structure of atomic thickness, including both single- and multi-layer variants thereof. Multi-layer two-dimensional materials can include up to about 20 stacked layers.


A “defect” refers to an opening in a plane of a two-dimensional material. In an embodiment, the defect may be an intrinsic or native defect. Intrinsic or native defects are those resulting from preparation of the two-dimensional material in contrast to perforations which are selectively introduced into a sheet of two-dimensional material. Such intrinsic or native defects include, but are not limited to, lattice anomalies, pores, tears, cracks or wrinkles. Lattice anomalies can include, but are not limited to, carbon rings with other than 6 members (e.g. 5, 7 or 9 membered rings) in graphene or graphene-based materials, vacancies, interstitial defects (including incorporation of non-carbon atoms in the lattice), and grain boundaries. In an embodiment, the defect may be a non-intrinsic defect. Non-intrinsic defects are nanoscale apertures (e.g., pores, holes) formed by a defect formation process, wherein energy (e.g., heat, pressure, electromagnetic radiation and combinations and variations thereof) sufficient to break the chemical bonds of the two-dimensional material is applied to at least one target location of the material. A plurality of non-intrinsic defects may be provided in a uniform or non-uniform (i.e., random) distribution or pattern. Typically, non-intrinsic defects are produced in at a target location of a two-dimensional material with precision of ±50 nm, ±10 nm or ±5 nm. In some embodiments, nanoscale apertures in a two-dimensional material are separated by an average closest edge-to-edge distance less than or equal to 20 nm or less than or equal to 15 nm or less than or equal to 10 nm.


A defect healing process, as used herein, refers to a process for partially or completely closing one or more openings (defects) in a two-dimensional material. A defect healing process may transform a perforated two-dimensional material into a less perforated or unperforated two-dimensional material using chemical techniques (e.g., bonding), physical techniques (e.g., blocking) or a combination of chemical and physical techniques. Exemplary healing techniques include, but are not limited to, reforming the crystallographic lattice of the two-dimensional material within the defect area, filling the defect with a material other than the two-dimensional material (e.g., epoxy), and covering the defect with a section of the same or different material, which at least partially overlaps the two-dimensional material. In an embodiment, the process of reforming the crystallographic lattice of the two-dimensional material within the defect area utilizes hydrocarbon-based surface contamination that is mobilized by the addition of energy. In an embodiment, the healing may be performed via a reorganization of existing defects without adding any new material.


“In situ” methods of the present invention are performed on a sample that remains in position throughout the method. For example, a sample that remains “in position” is stationary or does not leave a sample chamber during the in situ method. In situ methods according to the inventive concepts disclosed herein are useful for providing data indicative of a spatial and/or temporal change of a sample that remains in its original position. In some embodiments, an in situ method processes (e.g., perforates or heals) the sample and simultaneously interrogates the sample to provide substantially instantaneous, real-time data. In some embodiments, an in situ method processes (e.g., perforates or heals) the sample and performs nearly simultaneously interrogation of the sample to provide substantially near real-time data.


As described above, the incident radiation, and the scattered, emitted or transmitted radiation may be any one or more of electromagnetic radiation, electrons, ions, nanoparticles, or plasma. In an embodiment, incident radiation is processing radiaton, such as perforating or healing radiation or interrogating radiation. The incident radiation may also be both processing radiation and interrogating radiation. As described herein, processing radiation performs a process on the material when incident thereon.


In some embodiments, the incident perforating or healing radiation may also be interrogating radiation, which interacts with the two-dimensional material to produce scattered, emitted or transmitted radiation that is detected by a detector to provide data indicative of defect formation or healing. In an embodiment, the incident perforating or healing radiation is separate from interrogating radiation, which is produced by an alternate source and which interacts with the two-dimensional material to produce scattered, emitted or transmitted radiation that is detected by a detector to provide data indicative of defect formation or healing.


In an embodiment, the incident radiation does not perforate the two-dimensional material. The incident non-perforating radiation may interrogate the two-dimensional material by interacting with the two-dimensional material to produce scattered, emitted or transmitted radiation that is detected by a detector to provide data indicative of defect formation or healing.


In some embodiments, especially for methods configured for local sampling, micromechanical shutters disposed between the two-dimensional material and the detector could be opened and closed to allow for targeted sampling. Activation of the micromechanical shutters could be implemented by each shutter being biased to collect current from a respective local portion of the material. In an embodiment, the shutters may be arranged in an array over the two dimensional material, each shutter corresponding to a respective local portion. Thus, the respective local portion of the material may be electronically monitored by actuating its respective shutter to open to allow for appropriate radiation to be incident on the respective portion, and the electrical conductivity data of the local portion may be acquired. The shutters may be electrostatically actuated. When the emitted current divided by the bias current is not equal to 1, the actuator may move because the charge on the shutter moves the shutter by coulombic force. Other ways of moving the actuator once the appropriate signal is received are contemplated. In an embodiment, the shutters may be arranged in a two-dimensional array. In another embodiment, the shutters may be arranged in a one-dimensional array.


In some embodiments, probes, such as wires, could be contacted with respective local portions of the two-dimensional material to acquire electrical conductivity data. Thus, the electrical conductivity of the respective local portions may be monitored.


In embodiments, the two-dimensional material is a graphene-based material. In embodiments, the two-dimensional material is graphene.


In embodiments, at least a portion of the holes in the two-dimensional material are functionalized.


Additionally, the conductive properties of graphene-based or other two-dimensional membranes can allow for electrification to take place from an external source. In exemplary embodiments, an AC or DC voltage can be applied to conductive two-dimensional materials.


In some embodiments, the two-dimensional material, such as graphene, can be affixed to a suitable porous substrate. Suitable porous substrates can include, for example, thin film polymers and ceramics. Useful exemplary ceramics include nanoporous silica or SiN. Useful porous polymer substrates include track-etched polymers, expanded polymers or non-woven polymers. The substrate material can be porous or permeable.



FIG. 1 shows a graphene sheet 10 of carbon atoms defining a repeating pattern of hexagonal ring structures that collectively form a two-dimensional honeycomb lattice. An interstitial aperture 12 of less than 1 nm in diameter is formed by each hexagonal ring structure in the sheet. More particularly, the interstitial aperture in a perfect crystalline graphene lattice is estimated to be about 0.23 nanometers across its longest dimension. Accordingly, graphene materials preclude transport of any molecule across the graphene sheet's thickness unless there are pores, perforation-induced or intrinsic. The thickness of a theoretically perfect single graphene sheet is approximately 0.3 nm. Further, graphene has a breaking strength about 200 times that of steel, a spring constant in the range 1 N/m to 5 N/m and a Young's modulus of about 0.5 TPa.



FIG. 2 shows a flowchart 200 for a method for monitoring defect formation or healing via detection of scattered, emitted or transmitted radiation, according to an embodiment of the inventive concepts disclosed herein. Step 202 involves providing a material having a surface. In step 204, the surface of the material is exposed to incident radiation. In step 206, scattered, emitted or transmitted radiation are detected from at least a portion of the material exposed to the incident radiation, and in step 208 data indicative of defect formation or healing is generated. Typically, the method is performed in situ and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof.



FIG. 3 shows a flowchart 300 for a method for monitoring defect formation or healing via detection of movement of an analyte, according to an embodiment according to inventive concepts disclosed herein. Step 302 involves providing a material having a surface. In step 304, the surface of the material is exposed to incident radiation. In step 306, movement of an analyte through defects in the material is detected, and in step 308 data indicative of defect formation or healing is generated. Typically, the method is performed in situ and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, a maximum size of the defects, or combinations thereof.



FIG. 4 shows a flowchart 400 for a method for monitoring defect formation or healing via measurement of electrical conductivity, according to an embodiment according to inventive concepts disclosed herein. In step 402, a material having a surface is provided and in step 404 the surface of the material is exposed to incident radiation. In step 406, an electrical bias is applied to the material. In step 408, electrical conductivity is measured with a conductive probe in electrical contact with the material. In step 410, data indicative of defect formation or healing is generated. Typically, the method is performed in situ and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof. In an embodiment, a conductive probe is a conductive grid or a local probe. In an embodiment, defect density and electrical conductivity are inversely related such that an increase in defect density is observed as a decrease in electrical conductivity.



FIG. 5 shows a flowchart 500 for a method for monitoring defect formation or healing via Joule heating and temperature measurement, according to an embodiment according to inventive concepts disclosed herein. In step 502, a material having a surface is provided and the surface of the material is exposed to incident radiation, in step 504. In step 506, the material is heated. Subsequently, temperature of the surface of the material is measured in step 508. In step 510, data indicative of defect formation or healing is generated. Typically, the method is performed in situ and the data indicative of defect formation or healing provides a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof. In an embodiment, the step of heating the material comprises applying a potential to the two-dimensional material to induce joule heating. In an embodiment, defect density and thermal conductivity are inversely related such that an increase in defect density is observed as a decrease in thermal conductivity.


In embodiments, examples of which are schematically illustrated in FIGS. 6A and 6B, a system 600 for monitoring a two-dimensional material comprises a source 602 for delivering incident radiation 604 to a two-dimensional material 606, a detector 608 for receiving scattered, emitted or transmitted radiation or particles 610 from the two-dimensional material 606, and a processor 612 for receiving at least one signal 614 from the detector 608 and transforming the signal 614 into data indicative of defect formation or healing 622. The data 622 may be stored in a register or memory of the processor. In the embodiment shown in FIG. 6A, the detector 608 is positioned on the same side of the two-dimensional material 606 as the source 602 to receive scattered or emitted radiation or particles 610. In the embodiment shown in FIG. 6B, the detector 608 is positioned on the opposite side of the two-dimensional material 606 relative to the source 602 so that the detector 608 can receive transmitted radiation or particles 610. In an embodiment (not shown), a system 600 may include two or more detectors 608 positioned on one or both sides of the two-dimensional material 606. Optionally, the system 600 may also include a controller 616 that receives input 617 from the processor and provides control signals 618 to adjust the incident radiation 604 or a rate of sample translation in response to the data indicative of defect formation or healing 622 and/or a display 620 for visualizing the data. The rate of sample translation may be controlled by translation means, such as rollers 624 and/or a translation stage. Those of skill in the art will appreciate that for some methods disclosed herein the detector may be located on the same side of the two-dimensional material as the incident radiation source. Such configurations typically utilize detectors that are off-axis between about 15° and 75° relative to the trajectory of the incident radiation beam in order to protect the detector from damage. However, other methods disclosed herein may include a detector located on the opposite side of the two-dimensional material from the incident radiation source. Detectors that may be used in the methods disclosed herein include, but are not limited to, electron detectors, mass spectrometers, electromagnetic spectrometers, microbalances, Faraday cups, charge-coupled devices, ion detectors, resistors, capacitors, thermocouples, microchannel plates, phosphor screens, photodiodes and thermistors.


Inventive concepts disclosed herein will now be described with reference to the following non-limiting example.


EXAMPLE
In Situ Monitoring of Graphene Defect Formation or Healing

Suspended graphene on a substrate is loaded into an ion chamber on a platen and pumped down to 10−6-10−7 Torr while being heated to 50° C. Once the pressure is achieved the ion source (Kaufman source), which is a Xe+ beam of approximately 1 mm diameter at 300V and a beam current of 100 nA/mm2 (6.24×1013 Xe+/cm2·s), is rastered across the sample. The beam dwells such that the FWHM of the beam profile touches the previous dwell location. The dwell time for each spot is determined by monitoring the secondary electron (SE) emission from the incoming Xe+ using an Everhart-Thornley detector and is compared to known yields (defined as SE emitted for given incident ions in this case) for a given desired pore size, on a particular substrate, with these conditions (i.e. ion voltage, flux, etc.) which were previously acquired empirically. Once the proper SE electron yield is achieved (e.g., actual values match target values on a look-up table), a processor of the control system sends instructions to the instrument to move the beam to the next defect or healing location. The system also accounts for changes in expected yield over time as irradiation progresses.


Statements Regarding Incorporation by Reference and Variations

Although devices and methods have been described with reference to the disclosed embodiments, one having ordinary skill in the art will readily appreciate that these are only illustrative. It should be understood that various modifications can be made without departing from the spirit of the disclosure. The disclosure can be modified to incorporate any number of variations, alterations, substitutions or equivalent arrangements not heretofore described, but which are commensurate with the spirit and scope of the disclosure. Additionally, while various embodiments have been described, it is to be understood that aspects of the disclosure may include only some of the described embodiments. Accordingly, the disclosure is not to be seen as limited by the foregoing description.


Every formulation or combination of components described or exemplified can be used to practice the invention, unless otherwise stated. Specific names of compounds are intended to be exemplary, as it is known that one of ordinary skill in the art can name the same compounds differently. When a compound is described herein such that a particular isomer or enantiomer of the compound is not specified, for example, in a formula or in a chemical name, that description is intended to include each isomer and enantiomer of the compound described individually or in any combination. One of ordinary skill in the art will appreciate that methods, device elements, starting materials and synthetic methods other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents, of any such methods, device elements, starting materials and synthetic methods are intended to be included in this invention. Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure.


As used herein, “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim element. As used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any recitation herein of the term “comprising”, particularly in a description of components of a composition or in a description of elements of a device, is understood to encompass those compositions and methods consisting essentially of and consisting of the recited components or elements. The inventive concepts illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.


The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.


In general the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art. The preceding definitions are provided to clarify their specific use in the context of the invention.


All references throughout this application, for example patent documents including issued or granted patents or equivalents; patent application publications; and non-patent literature documents or other source material; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in this application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).


All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art, in some cases as of their filing date, and it is intended that this information can be employed herein, if needed, to exclude (for example, to disclaim) specific embodiments that are in the prior art. For example, when a compound is claimed, it should be understood that compounds known in the prior art, including certain compounds disclosed in the references disclosed herein (particularly in referenced patent documents), are not intended to be included in the claims.

Claims
  • 1. A method for monitoring defect formation or healing, comprising: exposing a surface of a material to incident radiation, the material being a two-dimensional material including a graphene or graphene-based film;detecting scattered, emitted and/or transmitted radiation from at least a portion of the material exposed to the incident radiation; andgenerating data indicative of defect formation or healing, wherein the method is performed in situ where the defect formation or healing occurs and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof.
  • 2. The method of claim 1, wherein the step of exposing the surface of the material to incident radiation produces a plurality of defects in the material.
  • 3. The method of claim 1, wherein the step of detecting radiation or particles comprises: (i) performing secondary ion mass spectroscopy;(ii) performing Raman spectroscopy;(iii) performing residual gas analysis on particles being removed from the material;(iv) detecting back scattered radiation or particles;(v) detecting Auger electrons;(vi) performing scanning probe microscopy;(vii) performing scanning tunneling microscopy;(viii) performing atomic force microscopy;(ix) performing X-ray photoelectron spectroscopy;(x) performing transmission electron microscopy;(xi) detecting nanoparticles on one or more microbalances or Faraday cups positioned behind the material;(xii) performing small angle electron diffraction;(xiii) detecting nanoparticles on a surface positioned behind the material using surface enhanced Raman scattering (SERS);(xiv) detecting secondary electrons;(xv) detecting transmitted electron or ions; or(xvi) performing a combination of two or more of (i)-(xv).
  • 4. The method of claim 3, wherein the back scattered radiation are selected from the group consisting of electrons, protons, helium, gallium, neon, argon, xenon or ions.
  • 5. The method of claim 1, wherein the step of generating data indicative of defect formation comprises determining secondary electron yield.
  • 6. The method of claim 1, wherein the steps of exposing and detecting occur simultaneously.
  • 7. The method of claim 1, wherein the incident radiation is perforating radiation, interrogating radiation or both.
  • 8. The method of claim 1, wherein the incident radiation and the scattered, emitted and/or transmitted radiation are the same type of radiation or different types of radiation.
  • 9. The method of claim 1, wherein the scattered, emitted or transmitted radiation results from the incident radiation or an additional source of interrogating radiation.
  • 10. The method of claim 1, wherein the scattered, emitted and/or transmitted radiation from the material is collected from a bulk portion of the surface having an area between 1 μm2 and 100 cm2.
  • 11. The method of claim 1, wherein the scattered, emitted and/or transmitted radiation from the material is collected from a local portion of the surface having an area between 100 nm2 and 10 mm2.
  • 12. The method of claim 1, wherein the scattered, emitted and/or transmitted radiation is continuously collected.
  • 13. The method of claim 1, wherein the incident radiation is pulsed, perforating radiation and the scattered, emitted and/or transmitted radiation is collected only when the incident radiation is off.
  • 14. The method of claim 1, wherein the emitted radiation is secondary electrons.
  • 15. A method for monitoring defect formation or healing, comprising: exposing a surface of a material to incident radiation, the material being a two-dimensional material including a graphene or graphene-based film;detecting movement of an analyte through defects in the material; andgenerating data indicative of defect formation or healing, wherein the method is performed in situ where the defect formation or healing occurs and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, a maximum size of the defects, or combinations thereof.
  • 16. The method of claim 15, wherein the step of detecting movement of the analyte through the defects in the material comprises one or more of: (i) determining the presence or absence of the analyte at a detector;(ii) quantifying the analyte;(iii) identifying a composition, mass, average radius, charge or size of the analyte;(iv) determining a rate of movement of the analyte through the defects in the material; or(v) a combination of two or more of (i)-(iv).
  • 17. The method of claim 15, wherein the analyte is a gas selected from the group consisting of hydrogen, helium, oxygen, nitrogen, xenon, neon, argon, SF6, H2O, CxH2x where x is 1 to 4, and combinations thereof.
  • 18. The method of claim 15, wherein the analyte is a plasma.
  • 19. The method of claim 15, wherein the incident radiation is a plasma and the analyte is one or more species of the plasma.
  • 20. A method for monitoring defect formation or healing, comprising: exposing a surface of a material to incident radiation;applying an electrical bias to the material, the material being a two-dimensional material including a graphene or graphene-based film;measuring electrical conductivity through a conductive probe in electrical contact with the material; andgenerating data indicative of defect formation or healing, wherein the method is performed in situ where the defect formation or healing occurs and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof.
  • 21. A method for monitoring defect formation or healing, comprising: exposing a surface of a material to incident radiation, the material being a two-dimensional material including a graphene or graphene-based film;heating the material;subsequently measuring temperature of the surface of the material; andgenerating data indicative of defect formation or healing, wherein the method is performed in situ where the defect formation or healing occurs and the data indicative of defect formation or healing provide a rate of defect formation or healing, a temporal change in the rate of defect formation or healing, a temporal change in the size of the defects, a spatial change in the rate of defect formation or healing, a spatial change in the size of the defects, or combinations thereof.
  • 22. The method of claim 1, wherein the incident radiation is a particle beam.
  • 23. The method of claim 22, wherein the particle beam produces a spot on the surface of the material, the spot having an area between 1 μm2 and 100 cm2.
  • 24. The method of claim 22, wherein the particle beam produces a spot on the surface of the material, the spot having an area between 1 nm2 and 10 mm2.
  • 25. The method of claim 22, wherein the particle beam is an ion beam.
  • 26. The method of claim 25, wherein the ion beam has an ion energy of at least 20 eV.
  • 27. The method of claim 25, wherein the ion beam has a flux selected from the range of 10 pA/mm2 to 1 μA/mm2.
  • 28. The method of claim 22, wherein the particle beam is an electron beam.
  • 29. The method of claim 28, wherein the electron beam has an energy of at least 10 eV.
  • 30. The method of claim 22, wherein the particle beam is a nanoparticle beam.
  • 31. The method of claim 30, wherein the nanoparticle beam has an energy of at least 1 keV per nanoparticle.
  • 32. The method of claim 30, wherein the nanoparticle beam has a flux selected from the range of 1.6×105 nanoparticles/s·cm2 to 1×1015 nanoparticles/s·cm2.
  • 33. The method of claim 1, wherein the two-dimensional material is a single atomic layer thick.
  • 34. The method of claim 1, wherein the material comprises a stack of two or more sheets of two-dimensional material, wherein each sheet is a single atomic layer thick.
  • 35. The method of claim 2, wherein the defects are pores having an average characteristic dimension less than or equal to 1 nm.
  • 36. The method of claim 2, wherein the defects are pores having an average characteristic dimension ranging from 0.3 nm to 100 nm.
  • 37. The method of claim 1, further comprising: comparing the data indicative of defect formation or healing to a threshold range for the data; andadjusting an energy or amount of the incident radiation if the data is outside of the threshold range.
  • 38. The method of claim 1, further comprising translating the material at a rate dependent upon a rate of defect formation or healing.
US Referenced Citations (641)
Number Name Date Kind
2187417 Doble Jan 1940 A
3024153 Kennedy Mar 1962 A
3303085 Price et al. Feb 1967 A
3501831 Gordon Mar 1970 A
3593854 Swank Jul 1971 A
3692059 Ice, Jr. Sep 1972 A
3701433 Krakauer et al. Oct 1972 A
3802972 Fleischer et al. Apr 1974 A
4073732 Lauer et al. Feb 1978 A
4159954 Gangemi Jul 1979 A
4162220 Servas Jul 1979 A
4277344 Cadotte Jul 1981 A
4303530 Shah et al. Dec 1981 A
4743371 Servas et al. May 1988 A
4855058 Holland et al. Aug 1989 A
4880440 Perrin Nov 1989 A
4889626 Browne Dec 1989 A
4891134 Vcelka Jan 1990 A
4925560 Sorrick May 1990 A
4935207 Stanbro et al. Jun 1990 A
4976858 Kadoya Dec 1990 A
5052444 Messerly et al. Oct 1991 A
5080770 Culkin Jan 1992 A
5082476 Kahlbaugh et al. Jan 1992 A
5156628 Kranz Oct 1992 A
5182111 Aebischer et al. Jan 1993 A
5185086 Kaali et al. Feb 1993 A
5201767 Caldarise et al. Apr 1993 A
5244981 Seidner et al. Sep 1993 A
5314492 Hamilton et al. May 1994 A
5314960 Spinelli et al. May 1994 A
5314961 Anton et al. May 1994 A
5331067 Seidner et al. Jul 1994 A
5344454 Clarke et al. Sep 1994 A
5371147 Spinelli et al. Dec 1994 A
5425858 Farmer Jun 1995 A
5480449 Hamilton et al. Jan 1996 A
5514181 Light et al. May 1996 A
5516522 Peyman et al. May 1996 A
5549697 Caldarise Aug 1996 A
5562944 Kafrawy Oct 1996 A
5565210 Rosenthal et al. Oct 1996 A
5580530 Kowatsch et al. Dec 1996 A
5595621 Light et al. Jan 1997 A
5636437 Kaschmitter et al. Jun 1997 A
5639275 Baetge et al. Jun 1997 A
5641323 Caldarise Jun 1997 A
5658334 Caldarise et al. Aug 1997 A
5662158 Caldarise Sep 1997 A
5665118 Lasalle et al. Sep 1997 A
5671897 Ogg et al. Sep 1997 A
5679232 Fedor et al. Oct 1997 A
5679249 Fendya et al. Oct 1997 A
5687788 Caldarise et al. Nov 1997 A
5700477 Rosenthal et al. Dec 1997 A
5713410 Lasalle et al. Feb 1998 A
5716412 Decarlo et al. Feb 1998 A
5716414 Caldarise Feb 1998 A
5725586 Sommerich Mar 1998 A
5731360 Pekala et al. Mar 1998 A
5733503 Kowatsch et al. Mar 1998 A
5746272 Mastrorio et al. May 1998 A
5782286 Sommerich Jul 1998 A
5782289 Mastrorio et al. Jul 1998 A
5788916 Caldarise Aug 1998 A
5800828 Dionne et al. Sep 1998 A
5808312 Fukuda Sep 1998 A
5868727 Barr et al. Feb 1999 A
5897592 Caldarise et al. Apr 1999 A
5902762 Mercuri et al. May 1999 A
5906234 Mastrorio et al. May 1999 A
5910172 Penenberg Jun 1999 A
5910173 Decarlo et al. Jun 1999 A
5913998 Butler et al. Jun 1999 A
5922304 Unger Jul 1999 A
5925247 Huebbel Jul 1999 A
5932185 Pekala et al. Aug 1999 A
5935084 Southworth Aug 1999 A
5935172 Ochoa et al. Aug 1999 A
5954937 Farmer Sep 1999 A
5974973 Tittgemeyer Nov 1999 A
5976555 Liu et al. Nov 1999 A
5980718 Van Konynenburg et al. Nov 1999 A
6008431 Caldarise et al. Dec 1999 A
6013080 Khalili Jan 2000 A
6022509 Matthews et al. Feb 2000 A
6052608 Young et al. Apr 2000 A
6080393 Liu et al. Jun 2000 A
6093209 Sanders Jul 2000 A
6139585 Li Oct 2000 A
6152882 Prutchi Nov 2000 A
6156323 Verdicchio et al. Dec 2000 A
6193956 Liu et al. Feb 2001 B1
6209621 Treacy Apr 2001 B1
6213124 Butterworth Apr 2001 B1
6228123 Dezzani May 2001 B1
6264699 Noiles et al. Jul 2001 B1
6292704 Malonek et al. Sep 2001 B1
6309532 Tran et al. Oct 2001 B1
6346187 Tran et al. Feb 2002 B1
6375014 Garcera et al. Apr 2002 B1
6426214 Butler et al. Jul 2002 B1
6454095 Brisebois et al. Sep 2002 B1
6455115 Demeyer Sep 2002 B1
6461622 Liu et al. Oct 2002 B2
6462935 Shiue et al. Oct 2002 B1
6521865 Jones et al. Feb 2003 B1
6532386 Sun et al. Mar 2003 B2
6544316 Baker et al. Apr 2003 B2
6580598 Shiue et al. Jun 2003 B2
6654229 Yanagisawa et al. Nov 2003 B2
6659298 Wong Dec 2003 B2
6660150 Conlan et al. Dec 2003 B2
6661643 Shiue et al. Dec 2003 B2
6686437 Buchman et al. Feb 2004 B2
6692627 Russell et al. Feb 2004 B1
6695880 Roffman et al. Feb 2004 B1
6699684 Ho et al. Mar 2004 B2
6719740 Burnett et al. Apr 2004 B2
6905612 Dorian et al. Jun 2005 B2
6924190 Dennison Aug 2005 B2
7014829 Yanagisawa et al. Mar 2006 B2
7071406 Smalley et al. Jul 2006 B2
7092753 Darvish et al. Aug 2006 B2
7138042 Tran et al. Nov 2006 B2
7171263 Darvish et al. Jan 2007 B2
7175783 Curran Feb 2007 B2
7179419 Lin et al. Feb 2007 B2
7190997 Darvish et al. Mar 2007 B1
7267753 Anex et al. Sep 2007 B2
7306768 Chiga Dec 2007 B2
7357255 Ginsberg et al. Apr 2008 B2
7374677 McLaughlin et al. May 2008 B2
7381707 Lin et al. Jun 2008 B2
7382601 Yoshimitsu Jun 2008 B2
7434692 Ginsberg et al. Oct 2008 B2
7452547 Lambino et al. Nov 2008 B2
7459121 Liang et al. Dec 2008 B2
7460907 Darvish et al. Dec 2008 B1
7476222 Sun et al. Jan 2009 B2
7477939 Sun et al. Jan 2009 B2
7477940 Sun et al. Jan 2009 B2
7477941 Sun et al. Jan 2009 B2
7479133 Sun et al. Jan 2009 B2
7505250 Cho et al. Mar 2009 B2
7531094 McLaughlin et al. May 2009 B2
7600567 Christopher et al. Oct 2009 B2
7631764 Ginsberg et al. Dec 2009 B2
7650805 Nauseda et al. Jan 2010 B2
7674477 Schmid et al. Mar 2010 B1
7706128 Bourcier Apr 2010 B2
7761809 Bukovec et al. Jul 2010 B2
7786086 Reches et al. Aug 2010 B2
7866475 Doskoczynski et al. Jan 2011 B2
7875293 Shults et al. Jan 2011 B2
7935331 Lin May 2011 B2
7935416 Yang et al. May 2011 B2
7943167 Kulkarni et al. May 2011 B2
7960708 Wolfe et al. Jun 2011 B2
7998246 Liu et al. Aug 2011 B2
8109893 Lande Feb 2012 B2
8147599 McAlister Apr 2012 B2
8262943 Meng et al. Sep 2012 B2
8278106 Martinson et al. Oct 2012 B2
8308702 Batchvarova et al. Nov 2012 B2
8316865 Ochs et al. Nov 2012 B2
8329476 Pitkanen et al. Dec 2012 B2
8354296 Dimitrakopoulos et al. Jan 2013 B2
8361321 Stetson et al. Jan 2013 B2
8449504 Carter et al. May 2013 B2
8471562 Knizhnik Jun 2013 B2
8475689 Sun et al. Jul 2013 B2
8506807 Lee et al. Aug 2013 B2
8512669 Hauck Aug 2013 B2
8513324 Scales et al. Aug 2013 B2
8535726 Dai et al. Sep 2013 B2
8592291 Shi et al. Nov 2013 B2
8617411 Singh Dec 2013 B2
8666471 Rogers et al. Mar 2014 B2
8686249 Whitaker et al. Apr 2014 B1
8697230 Ago et al. Apr 2014 B2
8698481 Lieber et al. Apr 2014 B2
8715329 Robinson et al. May 2014 B2
8721074 Pugh et al. May 2014 B2
8734421 Sun et al. May 2014 B2
8744567 Fassih et al. Jun 2014 B2
8751015 Frewin et al. Jun 2014 B2
8753468 Caldwell et al. Jun 2014 B2
8759153 Elian et al. Jun 2014 B2
8808257 Pugh et al. Aug 2014 B2
8828211 Garaj et al. Sep 2014 B2
8840552 Brauker et al. Sep 2014 B2
8857983 Pugh et al. Oct 2014 B2
8861821 Osumi Oct 2014 B2
8894201 Pugh et al. Nov 2014 B2
8940552 Pugh et al. Jan 2015 B2
8950862 Pugh et al. Feb 2015 B2
8974055 Pugh et al. Mar 2015 B2
8975121 Pugh et al. Mar 2015 B2
8979978 Miller et al. Mar 2015 B2
8986932 Turner et al. Mar 2015 B2
8993234 Turner et al. Mar 2015 B2
8993327 McKnight et al. Mar 2015 B2
9014639 Pugh et al. Apr 2015 B2
9017937 Turner et al. Apr 2015 B1
9023220 Zurutuza et al. May 2015 B2
9028663 Stetson et al. May 2015 B2
9035282 Dimitrakopoulos et al. May 2015 B2
9045847 Batchvarova et al. Jun 2015 B2
9050452 Sun et al. Jun 2015 B2
9052533 Pugh et al. Jun 2015 B2
9056282 Miller et al. Jun 2015 B2
9062180 Scales et al. Jun 2015 B2
9067811 Bennett et al. Jun 2015 B1
9070615 Elian et al. Jun 2015 B2
9075009 Kim et al. Jul 2015 B2
9080267 Batchvarova et al. Jul 2015 B2
9095823 Fleming Aug 2015 B2
9096050 Bedell et al. Aug 2015 B2
9096437 Tour et al. Aug 2015 B2
9102111 Pugh et al. Aug 2015 B2
9108158 Yu et al. Aug 2015 B2
9110310 Pugh et al. Aug 2015 B2
9125715 Pugh et al. Sep 2015 B2
9134546 Pugh et al. Sep 2015 B2
9170646 Toner et al. Oct 2015 B2
9185486 Pugh Nov 2015 B2
9193587 Bennett Nov 2015 B2
9195075 Pugh et al. Nov 2015 B2
9225375 Pugh et al. Dec 2015 B2
9388048 Zhou et al. Jul 2016 B1
9425709 Hayashi et al. Aug 2016 B2
9437370 Chen et al. Sep 2016 B2
9463421 Fleming Oct 2016 B2
9505192 Stoltenberg et al. Nov 2016 B2
9545600 Miller et al. Jan 2017 B2
9567224 Bedworth Feb 2017 B2
9572918 Bachmann et al. Feb 2017 B2
9592475 Stoltenberg et al. Mar 2017 B2
9610546 Sinton et al. Apr 2017 B2
9708640 Wu et al. Jul 2017 B2
9713794 Choi et al. Jul 2017 B2
9742001 Zhamu et al. Aug 2017 B2
9870895 Bedworth Jan 2018 B2
10017852 Heise Jul 2018 B2
20010036556 Jen Nov 2001 A1
20010047157 Burnett et al. Nov 2001 A1
20010055597 Liu et al. Dec 2001 A1
20020079004 Sato et al. Jun 2002 A1
20020079054 Nakatani Jun 2002 A1
20020104435 Baker et al. Aug 2002 A1
20020115957 Sun et al. Aug 2002 A1
20020117659 Lieber et al. Aug 2002 A1
20020183682 Darvish et al. Dec 2002 A1
20020183686 Darvish et al. Dec 2002 A1
20030052354 Dennison Mar 2003 A1
20030134281 Evans Jul 2003 A1
20030138777 Evans Jul 2003 A1
20030146221 Lauer et al. Aug 2003 A1
20030159985 Siwy et al. Aug 2003 A1
20040018583 Ho et al. Jan 2004 A1
20040035787 Tanga et al. Feb 2004 A1
20040061253 Kleinmeyer et al. Apr 2004 A1
20040063097 Evans Apr 2004 A1
20040099324 Fraser et al. May 2004 A1
20040111968 Day et al. Jun 2004 A1
20040112865 McCullough et al. Jun 2004 A1
20040121488 Chang et al. Jun 2004 A1
20040142463 Walker et al. Jul 2004 A1
20040185730 Lambino et al. Sep 2004 A1
20040193043 Duchon et al. Sep 2004 A1
20040199243 Yodfat Oct 2004 A1
20040208796 Chiga Oct 2004 A1
20040217036 Ginsberg et al. Nov 2004 A1
20040241214 Kirkwood et al. Dec 2004 A1
20040251136 Lean et al. Dec 2004 A1
20050004508 Sun et al. Jan 2005 A1
20050004509 Sun et al. Jan 2005 A1
20050004550 Sun et al. Jan 2005 A1
20050010161 Sun et al. Jan 2005 A1
20050010192 Sun et al. Jan 2005 A1
20050015042 Sun et al. Jan 2005 A1
20050053563 Manissier et al. Mar 2005 A1
20050112078 Boddupalli et al. May 2005 A1
20050126966 Tanida et al. Jun 2005 A1
20050129633 Lin Jun 2005 A1
20050148996 Sun et al. Jul 2005 A1
20050170089 Lashmore et al. Aug 2005 A1
20050189673 Klug et al. Sep 2005 A1
20050226834 Lambino et al. Oct 2005 A1
20050238730 Le Fur et al. Oct 2005 A1
20060005381 Nishi et al. Jan 2006 A1
20060036332 Jennings Feb 2006 A1
20060073370 Krusic et al. Apr 2006 A1
20060093885 Krusic et al. May 2006 A1
20060121279 Petrik Jun 2006 A1
20060151382 Petrik Jul 2006 A1
20060166347 Faulstich et al. Jul 2006 A1
20060180604 Ginsberg et al. Aug 2006 A1
20060222701 Kulkarni et al. Oct 2006 A1
20060253078 Wu et al. Nov 2006 A1
20070004640 Lin et al. Jan 2007 A1
20070032054 Ramaswamy et al. Feb 2007 A1
20070056894 Connors, Jr. Mar 2007 A1
20070060862 Sun et al. Mar 2007 A1
20070062856 Pahl et al. Mar 2007 A1
20070099813 Luizzi et al. May 2007 A1
20070131646 Donnelly et al. Jun 2007 A1
20070284279 Doskoczynski et al. Dec 2007 A1
20080017564 Hammond Jan 2008 A1
20080035484 Wu et al. Feb 2008 A1
20080035541 Franzreb et al. Feb 2008 A1
20080045877 Levin et al. Feb 2008 A1
20080061477 Capizzo Mar 2008 A1
20080063585 Smalley et al. Mar 2008 A1
20080081323 Keeley et al. Apr 2008 A1
20080081362 Keeley et al. Apr 2008 A1
20080149561 Chu et al. Jun 2008 A1
20080156648 Dudziak et al. Jul 2008 A1
20080170982 Zhang et al. Jul 2008 A1
20080185293 Klose et al. Aug 2008 A1
20080188836 Weber et al. Aug 2008 A1
20080190508 Booth et al. Aug 2008 A1
20080241085 Lin et al. Oct 2008 A1
20080268016 Fang et al. Oct 2008 A1
20080290020 Marand et al. Nov 2008 A1
20080290111 Ginsberg et al. Nov 2008 A1
20090023572 Backes et al. Jan 2009 A1
20090032475 Ferrer et al. Feb 2009 A1
20090039019 Raman Feb 2009 A1
20090048685 Frigstad et al. Feb 2009 A1
20090075371 Keeley et al. Mar 2009 A1
20090078640 Chu et al. Mar 2009 A1
20090087395 Lin et al. Apr 2009 A1
20090117335 Iyoda et al. May 2009 A1
20090148495 Hammer et al. Jun 2009 A1
20090176159 Zhamu et al. Jul 2009 A1
20090222072 Robinson et al. Sep 2009 A1
20090236295 Braun et al. Sep 2009 A1
20090241242 Beatty et al. Oct 2009 A1
20090283475 Hylton et al. Nov 2009 A1
20090291270 Zettl et al. Nov 2009 A1
20090294300 Kanzius et al. Dec 2009 A1
20090306364 Beer et al. Dec 2009 A1
20100000754 Mann et al. Jan 2010 A1
20100016778 Chattopadhyay Jan 2010 A1
20100021708 Kong et al. Jan 2010 A1
20100024722 Ochs et al. Feb 2010 A1
20100024838 Ochs et al. Feb 2010 A1
20100025330 Ratto et al. Feb 2010 A1
20100055464 Sung Mar 2010 A1
20100059378 Elson et al. Mar 2010 A1
20100072643 Pugh et al. Mar 2010 A1
20100076553 Pugh et al. Mar 2010 A1
20100105834 Tour et al. Apr 2010 A1
20100110372 Pugh et al. May 2010 A1
20100124564 Martinson et al. May 2010 A1
20100127312 Grebel et al. May 2010 A1
20100161014 Lynch et al. Jun 2010 A1
20100167551 Dedontney Jul 2010 A1
20100196439 Beck et al. Aug 2010 A1
20100209330 Golzhauser et al. Aug 2010 A1
20100209515 Chantalat et al. Aug 2010 A1
20100213079 Willis Aug 2010 A1
20100224555 Hoek et al. Sep 2010 A1
20100228204 Beatty et al. Sep 2010 A1
20100233781 Bangera et al. Sep 2010 A1
20100249273 Scales et al. Sep 2010 A1
20100258111 Shah et al. Oct 2010 A1
20100323177 Ruoff et al. Dec 2010 A1
20100327847 Leiber et al. Dec 2010 A1
20110014217 Fahmy et al. Jan 2011 A1
20110037033 Green et al. Feb 2011 A1
20110041519 McAlister Feb 2011 A1
20110041687 Diaz et al. Feb 2011 A1
20110045523 Strano et al. Feb 2011 A1
20110054418 Pugh et al. Mar 2011 A1
20110054576 Robinson et al. Mar 2011 A1
20110056892 Lancaster Mar 2011 A1
20110073563 Chang et al. Mar 2011 A1
20110092054 Seo et al. Apr 2011 A1
20110092949 Wang Apr 2011 A1
20110100921 Heinrich May 2011 A1
20110112484 Carter et al. May 2011 A1
20110118655 Fassih et al. May 2011 A1
20110120970 Joo et al. May 2011 A1
20110124253 Shah et al. May 2011 A1
20110132834 Tomioka et al. Jun 2011 A1
20110139707 Siwy et al. Jun 2011 A1
20110152795 Aledo et al. Jun 2011 A1
20110189440 Appleby Aug 2011 A1
20110201201 Arnold et al. Aug 2011 A1
20110202201 Matsubara Aug 2011 A1
20110253630 Bakajin et al. Oct 2011 A1
20110258791 Batchvarova et al. Oct 2011 A1
20110258796 Batchvarova et al. Oct 2011 A1
20110262645 Batchvarova et al. Oct 2011 A1
20110263912 Miller et al. Oct 2011 A1
20110269920 Min et al. Nov 2011 A1
20120000845 Park et al. Jan 2012 A1
20120031833 Ho et al. Feb 2012 A1
20120048804 Stetson et al. Mar 2012 A1
20120115243 Pitkanen et al. May 2012 A1
20120116228 Okubo May 2012 A1
20120145548 Sivan et al. Jun 2012 A1
20120148633 Sun et al. Jun 2012 A1
20120162600 Pugh et al. Jun 2012 A1
20120183738 Zettl et al. Jul 2012 A1
20120186850 Sugiyama et al. Jul 2012 A1
20120211367 Vecitis Aug 2012 A1
20120218508 Pugh et al. Aug 2012 A1
20120219203 Adachi Aug 2012 A1
20120220053 Lee et al. Aug 2012 A1
20120234453 Pugh et al. Sep 2012 A1
20120234679 Garaj et al. Sep 2012 A1
20120235277 Pugh et al. Sep 2012 A1
20120236254 Pugh et al. Sep 2012 A1
20120236524 Pugh et al. Sep 2012 A1
20120241371 Revanur et al. Sep 2012 A1
20120242953 Pugh et al. Sep 2012 A1
20120255899 Choi et al. Oct 2012 A1
20120267337 Striemer et al. Oct 2012 A1
20120292245 Saito Nov 2012 A1
20120298396 Hong et al. Nov 2012 A1
20120301707 Kinloch et al. Nov 2012 A1
20130015136 Bennett Jan 2013 A1
20130034760 Otts et al. Feb 2013 A1
20130045523 Leach et al. Feb 2013 A1
20130056367 Martinez et al. Mar 2013 A1
20130071941 Miller Mar 2013 A1
20130096292 Brahmasandra et al. Apr 2013 A1
20130100436 Jackson et al. Apr 2013 A1
20130105417 Stetson et al. May 2013 A1
20130108839 Arnold et al. May 2013 A1
20130116541 Gracias et al. May 2013 A1
20130131214 Scales et al. May 2013 A1
20130135578 Pugh et al. May 2013 A1
20130146221 Kolmakov et al. Jun 2013 A1
20130146480 Garaj et al. Jun 2013 A1
20130152386 Pandojirao-S et al. Jun 2013 A1
20130174968 Vlassiouk et al. Jul 2013 A1
20130174978 Pugh et al. Jul 2013 A1
20130176030 Simon Jul 2013 A1
20130190476 Lancaster et al. Jul 2013 A1
20130192460 Miller et al. Aug 2013 A1
20130192461 Miller et al. Aug 2013 A1
20130194540 Pugh et al. Aug 2013 A1
20130213568 Pugh et al. Aug 2013 A1
20130215377 Pugh et al. Aug 2013 A1
20130215378 Pugh et al. Aug 2013 A1
20130215380 Pugh et al. Aug 2013 A1
20130216581 Fahmy et al. Aug 2013 A1
20130240355 Ho et al. Sep 2013 A1
20130240437 Rodrigues et al. Sep 2013 A1
20130248097 Ploss, Jr. Sep 2013 A1
20130248367 Stetson et al. Sep 2013 A1
20130249147 Bedworth Sep 2013 A1
20130256118 Meller et al. Oct 2013 A1
20130256139 Peng Oct 2013 A1
20130256154 Peng Oct 2013 A1
20130256210 Fleming Oct 2013 A1
20130256211 Fleming Oct 2013 A1
20130261568 Martinson et al. Oct 2013 A1
20130269819 Ruby et al. Oct 2013 A1
20130270188 Karnik et al. Oct 2013 A1
20130273288 Luo et al. Oct 2013 A1
20130277305 Stetson et al. Oct 2013 A1
20130277573 Miller et al. Oct 2013 A1
20130284665 Lee et al. Oct 2013 A1
20130295150 Chantalat et al. Nov 2013 A1
20130309776 Drndic et al. Nov 2013 A1
20130317131 Scales et al. Nov 2013 A1
20130317132 Scales et al. Nov 2013 A1
20130317133 Scales et al. Nov 2013 A1
20130323295 Scales et al. Dec 2013 A1
20130335092 Wu Dec 2013 A1
20130338611 Pugh et al. Dec 2013 A1
20130338744 Frewin et al. Dec 2013 A1
20140002788 Otts et al. Jan 2014 A1
20140005514 Pugh et al. Jan 2014 A1
20140015160 Kung Jan 2014 A1
20140017322 Dai et al. Jan 2014 A1
20140030482 Miller et al. Jan 2014 A1
20140048411 Choi et al. Feb 2014 A1
20140066958 Priewe Mar 2014 A1
20140079936 Russo et al. Mar 2014 A1
20140093728 Shah et al. Apr 2014 A1
20140128891 Astani-Matthies et al. May 2014 A1
20140141521 Peng et al. May 2014 A1
20140151288 Miller et al. Jun 2014 A1
20140151631 Duesberg et al. Jun 2014 A1
20140154464 Miller et al. Jun 2014 A1
20140170195 Fassih et al. Jun 2014 A1
20140171541 Scales et al. Jun 2014 A1
20140174927 Bashir et al. Jun 2014 A1
20140190004 Riall et al. Jul 2014 A1
20140190550 Loh et al. Jul 2014 A1
20140190676 Zhamu et al. Jul 2014 A1
20140190833 Lieber et al. Jul 2014 A1
20140192313 Riall et al. Jul 2014 A1
20140192314 Riall et al. Jul 2014 A1
20140199777 Ruiz et al. Jul 2014 A2
20140209539 El Badawi et al. Jul 2014 A1
20140212596 Jahangiri-Famenini Jul 2014 A1
20140230653 Yu et al. Aug 2014 A1
20140230733 Miller Aug 2014 A1
20140231351 Wickramasinghe et al. Aug 2014 A1
20140248621 Collins Sep 2014 A1
20140253131 Liu Sep 2014 A1
20140257348 Priewe et al. Sep 2014 A1
20140257515 So et al. Sep 2014 A1
20140257517 Deichmann et al. Sep 2014 A1
20140259657 Riall et al. Sep 2014 A1
20140261999 Stetson et al. Sep 2014 A1
20140263035 Stoltenberg et al. Sep 2014 A1
20140263178 Sinton et al. Sep 2014 A1
20140264977 Pugh et al. Sep 2014 A1
20140268015 Riall et al. Sep 2014 A1
20140268020 Pugh et al. Sep 2014 A1
20140268021 Pugh et al. Sep 2014 A1
20140268026 Pugh et al. Sep 2014 A1
20140272286 Stoltenberg et al. Sep 2014 A1
20140272522 Pugh et al. Sep 2014 A1
20140273315 Pugh et al. Sep 2014 A1
20140273316 Pugh et al. Sep 2014 A1
20140276481 Pugh et al. Sep 2014 A1
20140276999 Harms et al. Sep 2014 A1
20140306361 Pugh et al. Oct 2014 A1
20140308681 Strano et al. Oct 2014 A1
20140311967 Grossman et al. Oct 2014 A1
20140315213 Nagrath et al. Oct 2014 A1
20140318373 Wood et al. Oct 2014 A1
20140322518 Addleman et al. Oct 2014 A1
20140333892 Pugh et al. Nov 2014 A1
20140335661 Pugh et al. Nov 2014 A1
20140343580 Priewe Nov 2014 A1
20140346081 Sowden et al. Nov 2014 A1
20140346631 Karim Nov 2014 A1
20140349892 Van Der Zaag et al. Nov 2014 A1
20140350372 Pugh et al. Nov 2014 A1
20140377651 Kwon et al. Dec 2014 A1
20140377738 Bachmann et al. Dec 2014 A1
20150015843 Pugh et al. Jan 2015 A1
20150017918 Pugh et al. Jan 2015 A1
20150053627 Silin et al. Feb 2015 A1
20150057762 Harms et al. Feb 2015 A1
20150061990 Toner et al. Mar 2015 A1
20150062533 Toner et al. Mar 2015 A1
20150063605 Pugh Mar 2015 A1
20150066063 Priewe Mar 2015 A1
20150075667 McHugh et al. Mar 2015 A1
20150077658 Pugh et al. Mar 2015 A1
20150077659 Pugh et al. Mar 2015 A1
20150077660 Pugh et al. Mar 2015 A1
20150077661 Pugh et al. Mar 2015 A1
20150077662 Pugh et al. Mar 2015 A1
20150077663 Pugh et al. Mar 2015 A1
20150077699 De Sio et al. Mar 2015 A1
20150077702 Pugh et al. Mar 2015 A9
20150079683 Yager et al. Mar 2015 A1
20150087249 Pugh et al. Mar 2015 A1
20150096935 Mitra et al. Apr 2015 A1
20150098910 Mordas et al. Apr 2015 A1
20150101931 Garaj et al. Apr 2015 A1
20150105686 Vasan Apr 2015 A1
20150118318 Fahmy et al. Apr 2015 A1
20150122727 Karnik et al. May 2015 A1
20150137817 Wilson May 2015 A1
20150138454 Pugh et al. May 2015 A1
20150142107 Pugh et al. May 2015 A1
20150145155 Pugh et al. May 2015 A1
20150146162 Pugh et al. May 2015 A1
20150147474 Batchvarova et al. May 2015 A1
20150170788 Miller et al. Jun 2015 A1
20150174253 Sun et al. Jun 2015 A1
20150174254 Sun et al. Jun 2015 A1
20150182473 Bosnyak et al. Jul 2015 A1
20150185180 Ruhl et al. Jul 2015 A1
20150196579 Ferrante et al. Jul 2015 A1
20150202351 Kaplan et al. Jul 2015 A1
20150212339 Pugh et al. Jul 2015 A1
20150217219 Sinsabaugh et al. Aug 2015 A1
20150218210 Stetson et al. Aug 2015 A1
20150221474 Bedworth Aug 2015 A1
20150231557 Miller et al. Aug 2015 A1
20150231577 Nair et al. Aug 2015 A1
20150247178 Mountcastle et al. Sep 2015 A1
20150258254 Simon et al. Sep 2015 A1
20150258498 Simon et al. Sep 2015 A1
20150258502 Turowski Sep 2015 A1
20150258503 Sinton et al. Sep 2015 A1
20150258506 Mi et al. Sep 2015 A1
20150258525 Westman et al. Sep 2015 A1
20150268150 Newkirk et al. Sep 2015 A1
20150272834 Sun et al. Oct 2015 A1
20150272896 Sun et al. Oct 2015 A1
20150273401 Miller et al. Oct 2015 A1
20150309337 Flitsch et al. Oct 2015 A1
20150321147 Fleming et al. Nov 2015 A1
20150321149 McGinnis Nov 2015 A1
20150323811 Flitsch et al. Nov 2015 A1
20150336202 Bedworth et al. Nov 2015 A1
20150342900 Putnins Dec 2015 A1
20150346382 Bliven Dec 2015 A1
20150351887 Peters Dec 2015 A1
20150359742 Fassih et al. Dec 2015 A1
20150378176 Flitsch et al. Dec 2015 A1
20160009049 Stoltenberg et al. Jan 2016 A1
20160038885 Hogen-Esch et al. Feb 2016 A1
20160043384 Zhamu et al. Feb 2016 A1
20160058932 Stetson et al. Mar 2016 A1
20160059190 Yoo et al. Mar 2016 A1
20160067390 Simon et al. Mar 2016 A1
20160074814 Park et al. Mar 2016 A1
20160074815 Sinton et al. Mar 2016 A1
20160084008 Faircloth Mar 2016 A1
20160084981 Kayano Mar 2016 A1
20160116237 Alsadah et al. Apr 2016 A1
20160256805 Grein et al. Sep 2016 A1
20160272499 Zurutuza et al. Sep 2016 A1
20160282326 Waduge et al. Sep 2016 A1
20160284811 Yu et al. Sep 2016 A1
20160339160 Bedworth et al. Nov 2016 A1
20170000937 Gottschalk Jan 2017 A1
20170032962 Zurutuza et al. Feb 2017 A1
20170035943 Simon et al. Feb 2017 A1
20170036916 Bedworth et al. Feb 2017 A1
20170037356 Simon et al. Feb 2017 A1
20170057812 Zurutuza et al. Mar 2017 A1
20170065939 Kim et al. Mar 2017 A1
20170144107 Garaj et al. May 2017 A1
20170202885 Agulnick Jul 2017 A1
20170216923 Babenko et al. Aug 2017 A1
20170217777 Hong et al. Aug 2017 A1
20170239623 Stoltenberg et al. Aug 2017 A1
20170296706 Simon et al. Oct 2017 A1
20170296972 Sinton et al. Oct 2017 A1
20170296976 Liu et al. Oct 2017 A1
20170296979 Swett et al. Oct 2017 A1
20180147542 Jhon et al. May 2018 A1
20180207591 Yu et al. Jul 2018 A1
Foreign Referenced Citations (109)
Number Date Country
2037988 Sep 1992 CA
2411935 Dec 2002 CA
1128501 Aug 1996 CN
101108194 Jan 2008 CN
101243544 Aug 2008 CN
101428198 May 2009 CN
101489653 Jul 2009 CN
101996853 Mar 2011 CN
102242062 Nov 2011 CN
102344132 Feb 2012 CN
102423272 Apr 2012 CN
102592720 Jul 2012 CN
101996853 Aug 2012 CN
102637584 Aug 2012 CN
103153441 Jun 2013 CN
103182249 Jul 2013 CN
203235358 Oct 2013 CN
103480281 Jan 2014 CN
103585891 Feb 2014 CN
103603706 Feb 2014 CN
19536560 Mar 1997 DE
10 2005 049 388 Apr 2007 DE
0 364 628 Apr 1990 EP
1 034 251 Jan 2004 EP
1 777 250 Apr 2007 EP
1 872 812 Jan 2008 EP
2 060 286 May 2009 EP
2 107 120 Oct 2009 EP
2 230 511 Sep 2010 EP
1 603 609 May 2011 EP
2 354 272 Aug 2011 EP
2 450 096 May 2012 EP
2 489 520 Aug 2012 EP
2 511 002 Oct 2012 EP
2 586 473 May 2013 EP
2 679 540 Jan 2014 EP
2 937 313 Oct 2015 EP
3 070 053 Sep 2016 EP
3 084 398 Oct 2016 EP
1 538 2430.5 Mar 2017 EP
3 135 631 Mar 2017 EP
59-102111 Jul 1984 JP
10-510471 May 1995 JP
7504120 May 1995 JP
2001-232158 Aug 2001 JP
2002-126510 May 2002 JP
2004-179014 Jun 2004 JP
2005-126966 May 2005 JP
2006-188393 Jul 2006 JP
2009-291777 Dec 2009 JP
2011-168448 Sep 2011 JP
2011-241479 Dec 2011 JP
2012-500708 Jan 2012 JP
2004-202480 Jul 2014 JP
2015-503405 Feb 2015 JP
2016-175828 Oct 2016 JP
102011008411 Jul 2011 KR
10-2012-0022164 Mar 2012 KR
1020120022164 Mar 2012 KR
1020140002570 Jan 2014 KR
WO-9333901 Mar 1993 WO
WO-9312859 Aug 1993 WO
WO-9500231 Jan 1995 WO
WO-9712664 Apr 1997 WO
WO-9830501 Jul 1998 WO
WO-0070012 Nov 2000 WO
WO-02055539 Jul 2002 WO
WO-2013115762 Aug 2003 WO
WO-2004009840 Jan 2004 WO
WO-2004082733 Sep 2004 WO
WO-2005047857 May 2005 WO
WO-2007103411 Sep 2007 WO
WO-2007140252 Dec 2007 WO
WO-2008008533 Jan 2008 WO
WO-2009129984 Oct 2009 WO
WO-2010006080 Jan 2010 WO
WO-2010115904 Oct 2010 WO
WO-2011019686 Feb 2011 WO
WO-2011046706 Apr 2011 WO
WO-2011001674 Jun 2011 WO
WO-2011063458 Jun 2011 WO
WO-2011075158 Jun 2011 WO
WO-2011094204 Aug 2011 WO
WO-2011100458 Aug 2011 WO
WO-2011138689 Nov 2011 WO
WO-2012006657 Jan 2012 WO
WO-2012021801 Feb 2012 WO
WO-2012027148 Mar 2012 WO
WO-2012028695 Mar 2012 WO
WO-2012030368 Mar 2012 WO
WO-2012125770 Sep 2012 WO
WO-2012138671 Oct 2012 WO
WO-2012142852 Oct 2012 WO
WO-2013016445 Jan 2013 WO
WO-2013048063 Apr 2013 WO
WO-2013138137 Sep 2013 WO
WO-2013138698 Sep 2013 WO
WO-2013151799 Oct 2013 WO
WO-2013152179 Oct 2013 WO
WO-2014084856 Jun 2014 WO
WO-2014084861 Jun 2014 WO
WO-2014168629 Oct 2014 WO
WO-2015030698 Mar 2015 WO
WO-2015110277 Jul 2015 WO
WO-2015138736 Sep 2015 WO
WO-2015138752 Sep 2015 WO
WO-20151138771 Sep 2015 WO
WO-2015197217 Dec 2015 WO
WO-2016102003 Jun 2016 WO
Non-Patent Literature Citations (430)
Entry
Allen et al., “Craters on silicon surfaces created by gas cluster ion impacts,” Journal of Applied Physics, 92(7): 3671-3678 (Oct. 2002).
Atmeh et al., “Albumin Aggregates: Hydrodynamic Shape and Physico-Chemical Properties,” Jordan Journal of Chemistry, 2(2): 169-182 (2007).
Chen et al., “Mechanically Strong, Electrically Conductive, and Biocompatible Graphene Paper,” Adv. Mater., 20(18): 3557-3561 (Sep. 2008) (available online Jul. 2008).
CN Office Action in Chinese Application No. 201380013988.9 dated Aug. 18, 2016 (English translation not readily available).
Fuertes, “Carbon composite membranes from Matrimid® and Kapton® polyimides for gas separation,” Microporous and Mesoporous Materials, 33: 115-125 (1991).
Galashev, “Computer study of the removal of Cu from the graphene surface using Ar clusters,” Computational Materials Science, 98: 123-128 (Feb. 2015) (available online Nov. 2014).
International Search Report and Written Opinion in PCT/US2015/013599 dated Jul. 20, 2015.
International Search Report and Written Opinion in PCT/US2015/013805 dated Apr. 30, 2015.
International Search Report and Written Opinion in PCT/US2015/018114 dated Jun. 3, 2015.
International Search Report and Written Opinion in PCT/US2015/020246 dated Jun. 10, 2015.
International Search Report and Written Opinion in PCT/US2015/020296 dated Jun. 17, 2015.
International Search Report and Written Opinion in PCT/US2015/028948 dated Jul. 16, 2015.
International Search Report and Written Opinion in PCT/US2015/029932 dated Oct. 6, 2015.
Inui et al., “Molecular dynamics simulations of nanopore processing in a graphene sheet by using gas cluster ion beam,” Appl. Phys. A, 98: 787-794 (Mar. 2010) (available online Dec. 2009).
Koh et al., “Sensitive NMR Sensors Detect Antibodies to Influenza,” NIH PA Author Manuscript PMC (Apr. 2009), also published in Angew. Chem. Int'l. Engl, 47(22): 4119-4121 (May 2008) (available online Apr. 2008).
Lehtinen et al., “Cutting and controlled modification of graphene with ion beams,” Nanotechnology, 22: 175306 (8 pages) (Mar. 2011).
Matteucci et al., “Transport of gases and Vapors in Glass and Rubbery Polymers,” in Materials Science of Membranes for Gas and Vapor Separation. (Yampolskii et al., eds. 2006) (available online Jun. 2006).
O'Hern et al., “Development of process to transfer large areas of LPCVD graphene from copper foil to a porous support substrate,” 1-62 (M.S. Thesis, Massachusetts Institute of Technology, Thesis) (Sep. 2011).
Plant et al. “Size-dependent propagation of Au nanoclusters through few-layer graphene,” Nanoscale, 6: 1258-1263 (2014) (available online Oct. 2013).
Popok. “Cluster Ion Implantation in Graphite and Diamond: Radiation Damage and Stopping of Cluster Constituents,” Reviews on Advanced Materials Science, 38(1): 7-16 (2014).
Russo et al., “Atom-by-atom nucleation and growth of graphene nanopores,” PNAS 109(16): 5953-5957 (Apr. 2012).
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated Aug. 12, 2016.
U.S. Office Action in U.S. Appl. No. 14/656,190 dated Aug. 29, 2016.
U.S. Office Action for U.S. Appl. No. 14/656,580 dated Jun. 2, 2016.
U.S. Office Action in U.S. Appl. No. 14/819,273 dated Jul. 6, 2016.
U.S. Office Action for U.S. Appl. No. 14/856,198 dated Jun. 3, 2016.
Yoon, “Simulations show how to turn graphene's defects into assets,” Sciencedaily (Oct. 4, 2016), www.sciencedaily.com/releases/2016/10/161004120428.htm.
Zabihi et al., “Formation of nanopore in a suspended graphene sheet with argon cluster bombardment: A molecular dynamics simulation study,” Nuclear Instruments and Methods in Physics Research B, 343: 48-51: (Jan. 2015) (available online Nov. 2014).
Zhang et al. Modern Thin-Film Technology 284-285 (Metallurgical Industry Press, 1st ed. 2009) (English translation not readily available).
Zhao et al. (2012), “Effect of SiO2 substrate on the irradiation-assisted manipulation of supported graphene: a molecular dynamics study,” Nanotechnology 23(28): 285703 (Jul. 2012) (available online Jun. 2012).
Zhao et al. (May 2012), “Drilling Nanopores in Graphene with Clusters: A Molecular Dynamics Study,” J. Phys. Chem. C, 116(21): 11776-11178 (2012) (available online May 2012).
Chen et al., “Hierarchically porous graphene-based hybrid electrodes with excellent electrochemical performance”, Journal of Materials Chemistry A: Materials for Energy and Sustainability, vol. 1, No. 33, Jan. 1, 2003, pp. 9409-9413.
Chinese Office Action in Application No. 201580006829.5 dated Jan. 23, 2018 (with English translation) (13 pages).
European Extended Search Report in Application No. 15786691.4 dated Dec. 1, 2017 (10 pages).
European Extended Search Report in Application No. 15789852.9 dated Dec. 6, 2017 (8 pages).
Japanese Office Action in Application No. 2017-042023 dated Jan. 9, 2018 (with English translation) (9 pages).
Singapore Search Report and Written Opinion in Application No. 11201701654U dated Dec. 6, 2017 (6 pages).
Taiwanese Office Action in Application No. 102146079 dated Dec. 12, 2017 (with English translation) (4 pages).
U.S. Notice of Allowance in U.S. Appl. No. 14/843,944 dated Feb. 9, 2018 (9 pages).
U.S. Office Action for U.S. Appl. No. 15/099,482 dated Feb. 23, 2018 (9 pages).
U.S. Office Action in U.S. Appl. No. 14/609,325 dated Jan. 16, 2018 (11 pages).
U.S. Office Action in U.S. Appl. No. 14/656,190 dated Jan. 10, 2018 (14 pages).
U.S. Office Action in U.S. Appl. No. 14/856,471 dated Jan. 11, 2018 (36 pages).
U.S. Office Action in U.S. Appl. No. 15/099,099 dated Feb. 15, 2018 (13 pages).
U.S. Office Action in U.S. Appl. No. 15/099,588 dated Feb. 1, 2018 (6 pages).
Wang et al., “Preparation of high-surface-area carbon nanoparticle/graphene composites”, Carbon, Elsevier, Oxford, GB, vol. 50, No. 10, Apr. 8, 2012, pp. 3845-3853.
Office Action for Indian Appl. Ser. No. 1566/DELNP/2013 dated Feb. 2, 2018 (7 pages).
Office Action for Japanese Appl. Ser. No. 2016-521448 dated Mar. 16, 2018 (5 pages).
Skrzypek et al., “Pancreatic islet macroencapsulation using microwell porous membranes”, Scientific Reports, 7: 9186 | DOI:10.1038/s41598-017-09647-7, Aug. 23, 2017 (12 pages).
U.S. Notice of Allowance for U.S. Appl. No. 15/099,464 dated Feb. 28, 2018 (5 pages).
U.S. Office Action for U.S. Appl. No. 15/099,276 dated Mar. 22, 2018 (13 pages).
U.S. Office Action for U.S. Appl. No. 15/453,441 dated Mar. 22, 2018 (7 pages).
Adiga et al., “Nanoporous Materials for Biomedical Devices,” JOM 60: 26-32 (Mar. 25, 2008).
AMI Applied Membranes Inc. (undated). FilmTec Nanofiltration Membrane Elements. Retrieved Jun. 1, 2016, from http://www.appliedmembranes.com/filmtec-nanofiltration-membrane-elements.html.
Apel, “Track etching technique in membrane technology,” Radiation Measurements 34(1-6): 559-566 (Jun. 2001).
Bae et al., “Roll-to-roll production of 30-inch graphene films for transparent electrodes,” Nature Nanotechnology 5: 574-578 (Jun. 20, 2010).
Bai et al., “Graphene nanomesh,” Nature Nanotechnology 5: 190-194 (Feb. 14, 2010).
Baker. (2004). Track-etch Membranes. In Membrane Technology and Applications (2nd ed., pp. 92-94). West Sussex, England: John Wiley & Sons.
Butler et al. “Progress, Challenges, and Opportunities in Two-Dimensional Materials Beyond Graphene”, Materials Review 7(4): 2898-2926 (Mar. 6, 2013).
Chhowalla et al., “The chemistry of two-dimensional layered transition metal dichalcogenide nanosheets,” Nature Chemistry 5: 263-275 (Mar. 20, 2013).
Childres et al., “Effect of oxygen plasma etching on graphene studied using Raman spectroscopy and electronic transport measurements,” New Journal of Physics 13 (Feb. 10, 2011).
Clochard. (undated). Radiografted track-etched polymer membranes for research and application [Scholarly project]. In Laboratoire Des Solides Irradiés. Retrieved Jun. 2, 2016, from http://iramis.cea.fr/radiolyse/5juin2015/Clochard.pdf.
Cohen-Tanugi et al, “Water Desalination across Nanoporous Graphene,” ACS Nano Letters 12(7): 3602-3608 (Jun. 5, 2012).
Cohen-Tanugi, “Nanoporous graphene as a water desalination membrane,” Thesis: Ph.D., Massachusetts Institute of Technology, Department of Materials Science and Engineering (Jun. 2015).
Colton, “Implantable biohybrid artificial organs,” Cell Transplantation 4(4): 415-436 (Jul.-Aug. 1995).
Desai et al., “Nanoporous microsystems for islet cell replacement,” Advanced Drug Delivery Reviews 56: 1661-1673 (Jul. 23, 2004).
Fischbein et al., “Electron beam nanosculpting of suspended graphene sheets,” Applied Physics Letters 93(113107): 1-3, (Sep. 16, 2008).
Fissell et al., “High-Performance Silicon Nanopore Hemofiltration Membranes,” NIH-PA Author Manuscript, PMC, (Jan. 5, 2010), also published in J. Memb. Sci. 326(1): 58-63 (Jan. 5, 2009).
Gimi et al., “A Nanoporous, Transparent Microcontainer for Encapsulated Islet Therapy,” J. Diabetes Sci. Tech. 3(2): 1-7 (Mar. 2009).
Jiang et al., “Porous Graphene as the Ultimate Membrane for Gas Separation,” Nano Letters 9(12): 4019-4024 (Sep. 23, 2009).
Joshi et al., “Precise and ultrafast molecular sieving through graphene oxide membranes”, Science 343(6172): 752-754 (Feb. 14, 2014).
Kanani et al., “Permeability—Selectivity Analysis for Ultrafiltration: Effect of Pore Geometry,” NIH-PA Author Manuscript, PMC, (Mar. 1, 2011), also published in J. Memb. Sci. 349(1-2): 405 (Mar. 1, 2010).
Karan et al., “Ultrafast Viscous Permeation of Organic Solvents Through Diamond-Like Carbon Nanosheets,” Science 335: 444-447 (Jan. 27, 2012).
Kim et al., “Fabrication and Characterization of Large Area, Semiconducting Nanoperforated Graphene Materials,” Nano Letters 10(4): 1125-1131 (Mar. 1, 2010).
Kim et al., “The structural and electrical evolution of graphene by oxygen plasma-induced disorder,” Nanotechnology IOP 20(375703): 1-8 (Aug. 26, 2009).
Koski and Cui, “The New Skinny in Two-Dimensional Nanomaterials”, ACS Nano 7(5): 3739-3743 (May 16, 2013).
Liu et al., “Atomically Thin Molybdenum Disulfide Nanopores with High Sensitivity for DNA Translocation,” ACS Nano 8(3): 2504-2511 (Feb. 18, 2014).
Liu et al., “Graphene Oxidation: Thickness-Dependent Etching and Strong Chemical Doping,” Nano Letters 8(7): 1965-1970 (Jun. 19, 2008).
Mishra et al., “Functionalized Graphene Sheets for Arsenic Removal and Desalination of Sea Water,” Desalination 282: 39-45 (Nov. 1, 2011).
Morse, “Scalable Synthesis of Semiconducting Nanopatterned Graphene Materials,” InterNano Resources for Nanomanufacturing (undated). Retrieved Jun. 2, 2016 from: http://www.internano.org/node/345.
Nair et al., “Unimpeded Permeation of Water Through Helium-Leak-tight Graphene-Based Membranes,” Science 335: 442-444 (Jan. 27, 2012).
O'Hern et al. “Selective Molecular Transport through Intrinsic Defects in a Single Layer of CVD Graphene,” ACS Nano, 6(11): 10130-10138 (Oct. 2, 2012).
O'Hern et al., “Selective Ionic Transport through Tunable Subnanometer Pores in Single-Layer Graphene Membranes,” Nano Letters 14(3): 1234-1241 (Feb. 3, 2014).
Paul, “Creating New Types of Carbon-Based Membranes,” Science 335: 413-414 (Jan. 27, 2012).
Schweicher et al., “Membranes to achieve immunoprotection of transplanted islets,” NIH-PA Author Manuscript, PMC, (Nov. 13, 2014), also published in Frontiers in Bioscience (Landmark Ed) 19: 49-76 (Jan. 1, 2014).
Sint et al., “Selective Ion Passage through Functionalized Graphene Nanopores,” JACS 130: 16448-16449 (Nov. 14, 2008).
Suk et al., “Water Transport Through Ultrathin Graphene,” Journal of Physical Chemistry Letters 1(10): 1590-1594 (Apr. 30, 2010).
Tan et al., “Beta-cell regeneration and differentiation: how close are we to the ‘holy grail’?” J. Mol. Encodrinol. 53(3): R119-R129 (Dec. 1, 2014).
Vlassiouk et al., “Versatile ultrathin nanoporous silicon nitride membranes,” Proc. Natl. Acad. Sci. USA 106(50): 21039-21044 (Dec. 15, 2009).
Wadvalla, “Boosting agriculture through seawater,” Nature Middle East (Jul. 2, 2012). Retrieved Jun. 1, 2016 from: natureasia.com/en/nmiddleeast/article/10.1038/nmiddleeast.2012.92?WT.mc_id=FBK NatureMEast].
Wikipedia, “Ion track.” Jun. 1, 2016. Retrieved Jun. 1, 2016 from: en.wikipedia.org/wiki/ion_track.
Xu et al., “Graphene-like Two-Dimensional Materials”, Chemical Reviews 113: 3766-3798 (Jan. 3, 2013).
Zan et al., “Graphene Reknits Its Holes,” Nano Lett. 12(8): 3936-3940 (Jul. 5, 2012).
Zhao et al. “Two-Dimensional Material Membranes: An Emerging Platform for Controllable Mass Transport Applications,” Small 10(22): 4521-4542 (Sep. 10, 2014).
AE Search and Examination Report for United Arab Emirates Application No. P186/13 dated Oct. 4, 2016.
Agenor et al., “Renal tubular dysfunction in human visceral leishmaniasis (Kala-azar),” Clinical Nephrology 71(5): 492-500 (May 2009) (available online Mar. 21, 2011).
Albert et al., “Ringer's lactate is compatible with the rapid infusion of AS-3 preserved packed red blood cells,” Can. J. Anaesth. 56(5): 352-356 (May 2009) (available online Apr. 2, 2009).
Aluru et al. “Modeling electronics on the nanoscale.” Handbook of nanoscience, engineering and technology Goddard W, Brenner D, Lyshevski S, Iafrate GJ (2002): 11-1.
Alvarenga, “Carbon nanotube materials for aerospace wiring” Rochester Institute of Technology, 2010.
AMI Applied Membranes Inc., “Filmtec Nanofiltration Membrane Elements”, Retrieved from appliedmembranes.com/nanofiltration_elements.htm, accessed Apr. 28, 2015 (2 Pages).
Aso et al., “Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin,” Diabetes 55(7): 1954-1960 (Jul. 2006).
AU Examination Report for Australian Patent Application No. 2013235234, dated Jan. 13, 2017, 4 pages.
AU Examination Report for Australian Patent Application No. 2013363283, dated Jun. 20, 2017, 4 pages.
AU Notice of Acceptance for Australian Application No. 2011293742 dated Jan. 13, 2016.
Axelsson et al., “Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats,” Am. J. Physiol. Renal Physiol. 298(6): F1306-F1312 (Jun. 2010) (available online Mar. 17, 2010).
Bains et al., “Novel lectins from rhizomes of two Acorus species with mitogenic activity and inhibitory potential towards murine cancer cell lines,” Int'l Immunopharmacol. 5(9): 1470-1478 (Aug. 2005) (available online May 12, 2005).
Baker, “Membrane Technology and Applications”, Membrane Technology and Applications; Apr. 14, 2004; pp. 92-94.
Barreiro et al. “Transport properties of graphene in the high-current limit.” Physical review letters 103.7 (2009): 076601.
Bazargani et al. “Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation,” Peritoneal Dialysis Int'l 25(4): 394-404 (Jul. 2005-Aug. 2005).
Bazargani, “Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms,” Swedish Dental J. Supp. 171: 1-57, i (2005).
Beppu et al., “Antidiabetic effects of dietary administration of Aloe arborescens Miller components on multiple low-dose streptozotocin-induced diabetes in mice: investigation on hypoglycemic action and systemic absorption dynamics of aloe components,” J. Ethnopharmacol. 103(3): 468-77 (Feb. 20, 2006) (available online Jan. 6, 2006).
Bieri et al. “Two-dimensional Polymer Formation on Surfaces: Insight into the Roles of Precursor Mobility and Reactivity” JACS, 2010, vol. 132, pp. 16669-16676.
Bruin et al., “Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice”, Diabetologia (2013), vol. 56: 1987-1998 (Jun. 16, 2013).
Chu Ju, et al. “Modern Biotechnology” East China University of Technology Press, (Sep. 2007), vol. 1; pp. 306-307, ISBN 978-7-5628-2116-8.
Clochard, “Track-Etched Polymer Membranes,” Laboratory of Irradiated Solids, Ecole Polytechnique, retrieved from http://www.lsi.polytechnique.fr/home/research/physics-and-chemistry-of-nano-objects/trac . . . , Accessed Jul. 30, 2015 (2 pages).
CN Notification of Grant for Chinese Application No. 201180049184.5 dated Jun. 6, 2016.
CN Office Action for Chinese Application No. 201380014845.X dated Jul. 8, 2016.
CN Office Action for Chinese Application No. 201380014845.X dated Sep. 2, 2015.
CN Office Action for Chinese Application No. 201380019165.5 dated Aug. 25, 2015.
CN Office Action for Chinese Application No. 201380073141.X dated Jun. 8, 2016.
CN Office Action for Chinese Application No. 201380073141.X dated Mar. 21, 2017.
CN Office Action for Chinese Application No. 201480015372.X dated Aug. 2, 2016.
CN Office Action for Chinese Application No. 20118004918.5 dated Jun. 15, 2015.
CN Office Action for Chinese Application No. 201180049184.5 dated Jul. 30, 2014.
CN Office Action for Chinese Application No. 201180049184.5 dated Mar. 4, 2016.
CN Office Action for Chinese Application No. 201380014845.X dated Dec. 23, 2016.
CN Office Action for Chinese Application No. 201380017644.5 dated Feb. 7, 2017.
CN Office Action for Chinese Application No. 201380017644.5 dated May 26, 2016.
CN Office Action for Chinese Application No. 201380017644.5 dated Sep. 29, 2015.
CN Office Action in Chinese Application No. 201380013988.9 dated Oct. 27, 2015.
Daniel et al. “Implantable Diagnostic Device for Cancer Monitoring.” Biosens Bioelectricon. 24(11): 3252-3257 (Jul. 15, 2009).
Database WPI, Week 201238, Thomson Scientific, London, GB; AN 2012-D49442.
De Lannoy et al., “Aquatic Biofouling Prevention by Electrically Charged Nanocomposite Polymer Thin Film Membranes”, 2013 American Water Work Association membrane Technology Conference; Environmental science & technology 47.6 (2013): 2760-2768.
Deng et al., “Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade,” Am. J. Physiol. Renal Physiol. 299(6): F1365-F1373 (Dec. 2010) (available online Sep. 29, 2010).
Edwards, “Large Sheets of Graphene Film Produced for Transparent Electrodes (w/ Video)”; (Jun. 21, 2010), PhysOrg.com, retrieved on May 15, 2017 from https://phys.org/news/2010-06-large-sheets-graphene-transparentelectrodes.html (2 pages).
EP Office Action for European Application No. 13715529.7 dated Jun. 24, 2016.
Fayerman, “Canadian scientists use stem cells to reverse diabetes in mice”, The Telegraph-Journal (New Brunswick), 1-2 (Jun. 29, 2012).
Fayerman, “Diabetes reversed in mice; University of B.C. scientists use embryonic stem cells to deal with Type 1 disease”, The Vancouver Sun (British Columbia), 1-2 (Jun. 28, 2012).
Fejes et al. “A review of the properties and CVD synthesis of coiled carbon nanotubes.” Materials 3.4 (2010): 2618-2642.
Franzen, C. “MIT Setting Up Industrial-Scale Graphene Printing Press” Sep. 23, 2011, retrieved from http://talkingpointsmemo.com/idealab/mit-setting-up-industrial-scale-graphene-printing-press (2 pages).
Freedman et al., “Genetic basis of nondiabetic end-stage renal disease,” Semin. Nephrol. 30(2): 101-110 (Mar. 2010).
Garcia-Lopez et al., “Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients,” Peritoneal Dialysis Int'l 25(2): 181-191 (Mar. 2005-Apr. 2005).
Georgakilas et al., “Functionalization of Graphene: Covalent and Non-Covalent Approaches, Derivatives and Applications,” Chem. Rev., (2012) 112(11), pp. 6156-6214.
Gnudi “Molecular mechanisms of proteinuria in diabetes,” Biochem. Soc. Trans. 36(5): 946-949 (Oct. 2008).
Gotloib et al., “Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation,” Nephrol. Dialysis. Transplant. 20(Supp. 7): vii32-vii36 (Jul. 2005).
Harvey “Carbon as conductor: a pragmatic view.” Proceedings of the 61st IWCS Conference, http://www. iwcs. org/archives/56333-iwcs-2012b-1.1584632. vol. 1. 2012.
Hashimoto et al. “Direct evidence for atomic defects in graphene layers.” Nature 430.7002 (2004): 870-873.
He, et al. “The attachment of Fe3 04 nanoparticles to graphene oxide by covalent bonding.” Carbon 48.11 (2010): 3139-3144.
Hone et al. “Graphene has record-breaking strength” Physicsworld.com, Jul. 17, 2008.
Huang et al., “Gene expression profile in circulating mononuclear cells afterexposure to ultrafine carbon particles,” Inhalation Toxicol. 22(10): 835-846 (Aug. 2010).
Humplik, et al. “Nanostructured materials for water desalination.” Nanotechnology 22.29 (2011): 292001.
International Search Report and Written Opinion dated Jan. 5, 2012 for related International Application No. PCT/US11/47800.
International Search Report and Written Opinion dated Jul. 5, 2017 from related PCT application PCT/US2017/024147.
International Search Report and Written Opinion dated Mar. 12, 2014 for International Application No. PCT/US2013/074942.
International Search Report and Written Opinion for International Application No. PCT/US2011/047800 dated Jan. 5, 2012.
International Search Report and Written Opinion for PCT Application No. PCT/US2014/023027 dated Jun. 26, 2014.
International Search Report and Written Opinion in International Application No. PCT/US2013/030344 dated Jun. 19, 2013.
International Search Report and Written Opinion in International Application No. PCT/US2013/033035 dated Jun. 28, 2013.
International Search Report and Written Opinion in International Application No. PCT/US2013/033400, dated Jun. 28, 2013.
International Search Report and Written Opinion in International Application No. PCT/US2013/033403 dated Jun. 28, 2013.
International Search Report and Written Opinion in PCT/US2014/041766, dated Sep. 30, 2014.
International Search Report and Written Opinion dated Jun. 5, 2014 in International Application No. PCT/US2014/021677.
International Search Report and Written Opinion dated Jun. 6, 2014 in International Application No. PCT/US2014/023043.
International Search Report and Written Opinion dated Dec. 16, 2014, for International Application No. PCT/US2014/051011.
International Search Report and Written Opinion dated Jun. 19, 2015, in International Application No. PCT/US2015/020287.
Inui et al. “Molecular dynamics simulations of nanopore processing in a graphene sheet by using gas cluster ion beam.” Applied Physics A: Materials Science & Processing 98.4 (2010): 787-794.
Israelachvili, “Intermolecular and Surface Forces,” 3rd ed., Chap.7.1, Sizes of Atoms, Molecules, and Ions, 2011, 1 page.
Jiao et al., “Castration differentially alters basal and leucine-stimulated tissue protein synthesis in skeletal muscle and adipose tissue,” Am. J. Physiol. Endocrinol. Metab. 297(5): E1222-1232 (Nov. 2009) (available online Sep. 15, 2009).
JP Office Action in Japanese Application No. 2015-501729 dated Dec. 9, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-501729 dated Jun. 20, 2017 (English translation).
JP Office Action in Japanese Application No. 2015-501867 dated Oct. 11, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-503405 dated Nov. 14, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-503406 dated Dec. 6, 2016(English translation).
Kang et al., “Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats,” Nephrol. Dialysis Transplant. 24(1): 73-84 (Jan. 2009).
Kang et al., “Efficient Transfer of Large-Area Graphene Films onto Rigid Substrates by Hot Pressing,” American Chemical Society Nano, 6(6): 5360-5365(May 28, 2012).
Kar et al., “Effect of glycation of hemoglobin on its interaction with trifluoperazine,” Protein J. 25(3): 202-211 (Apr. 2006) (available online Jun. 6, 2006).
Kawamoto et al., “Serum high molecular weight adiponectin is associated with mild renal dysfunction in Japanese adults,” J. Atherosclerosis Thrombosis 17(11): 1141-1148 (Nov. 27, 2011).
Khun et al. “From Microporous Regular Frameworks to Mesoporous Materials with Ultrahigh Surface Area: Dynamic reorganization of Porous Polvmer Networks” JACS, 2008; vol. 130; pp. 13333-13337.
Krupka et al., “Measurements of the Sheet Resistance and Conductivity of Thin Epitaxial Graphene and SiC Films” Applied Physics Letters 96, 082101-I; Feb. 23, 2010.
Kumar et al., “Modulation of alpha-crystallin chaperone activity in diabetic rat lens by curcumin,” Molecular Vision 11: 561-568 (Jul. 26, 2005).
Lathuiliere et al., “Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System,” Journal of Applied Physics, Int. J. Mol. Sci., 16: 10578-10600 (May 8, 2015).
Lee, et al. “Measurement of the elastic properties and intrinsic strength of monolayer graphene.” science 321.5887 (2008): 385-388.
Lucchese et al. “Quantifying ion-induced defects and Raman relaxation length in graphene.” Carbon 48.5 (2010): 1592-1597.
Macleod et al. “Supramolecular Orderinng in Oligothiophene-Fullerene Monolayers” JACS, 2009, vol. 131, pp. 16844-16850.
Mattevi et al. “A review of chemical vapour deposition of graphene on copper.” Journal of Materials Chemistry 21.10 (2011): 3324-3334.
Miao et al. “Chemical vapor deposition of grapheme” INTECH Open Access Publisher, 2011.
MIT/MTL Center for Graphene Devices and 2D Systems, retrieved from: http://www-mtl.mit.edu/wpmu/graphene/ [retrieved from Aug. 21, 2014 archive] (3 pages).
MIT/MTL Center for Graphene Devices and 2D Systems, retrieved from: http://www-mtl.mit.edu/wpmu/graphene/ [retrieved from Mar. 4, 2015 archive] (3 pages).
Nafea, et al. “Immunoisolating semi-permeable membranes for cell encapsulation: focus on hydrogels.” J Control Release. 154(2): 110-122 (Sep. 5, 2011).
Nezlin, “Circulating non-immune IgG complexes in health and disease,” Immunol. Lett. 122(2); 141-144 (Feb. 21, 2009) (available online Feb. 2, 2009).
Norata et al., “Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status,” Nutr. Metab. Cardiovasc. Dis. 20(1): 56-63 (Jan. 2010) (available online Apr. 9, 2009).
Ogawa et al., “Exosome-like vesicles in Gloydius blomhoffii blomhoffii venom,” Toxicon 51(6): 984-993 (May 2008) (available online Feb. 19, 2008).
Ohgawara et al. “Assessment of pore size of semipermeable membrane for immunoisolation on xenoimplatntation of pancreatic B cells using a diffusion chamber.” Transplant Proc. (6): 3319-3320. 1995.
Oki et al., “Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone,” J. Neurosurg. 110(2): 369-73 (Feb. 2009).
Osorio et al., “Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats,” Diabetes Res. Clin. Pract. 86(3): e46-e49 (Dec. 2009) (available online Oct. 2, 2009).
Osorio et al., “Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats,” J. Nephrol. 23(5): 541-546 (Sep.-Oct. 2010).
Padidela et al., “Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period,” Eur. J. Endocrinol. 160(1): 53-58 (Jan. 2009) (available online Oct. 24, 2008).
Pall Corporation, “Pall Water Processing Disc-Tube Filter Technology”, Retrieved on Feb. 10, 2015, Retrieved from http://www.pall.com /pdfs/Fuels-and-Chemicals/Disc-Tube_Filter_Technology-DT100b.pdF (15 Pages).
Plant et al. “Size-dependent propagation of Au nanoclusters through few-layer grapheme,” The Royal Society of Chemistry 2013, Nanoscale.
Pollard, “Growing Graphene via Chemical Vapor” Department of Physics, Pomona College; May 2, 2011.
Rafael et al. “Cell Transplantation and Immunoisolation: Studies on a macroencapsultaion device.” From the Departments of Transplantation Pathology: Stockholm, Sweden (1999).
Rezania et al., “Enrichment of Human Embryonic Stem Cell-Derived NKX6.1-Expressing Pancreatic Progenitor Cells Accelerates the Maturation of Insulin-Secreting Cells In Vivo”, Stem Cells Regenerative Medicine, vol. 31: 2432-2442 (Jul. 29, 2013).
Rezania et al., “Maturation of Human Embryonic Stem Cell-Derived Pancreatic Progenitors Into Functional Islets Capable of Treating Pre-existing Diabetes in Mice”, Diabetes Journal, vol. 61: 2016-2029 (Aug. 1, 2012).
Ribeiro et al., “Binary Mutual Diffusion Coefficients of Aqueous Solutions of Sucrose, Lactose, Glucose, and Fructose in the Temperature Range from (298.15 to 328.15) K,” J. Chem. Eng. Data 51(5): 1836-1840 (Sep. 2006) (available online Jul. 20, 2006).
Rippe et al., “Size and charge selectivity of the glomerular filter in early experimental diabetes in rats,” Am. J. Physiol. Renal Physiol. 293(5): F1533-F1538 (Nov. 2007)(available online Aug. 15, 2007).
SA Final Rejection for Saudi Arabia Application No. 113340400 dated Jan. 28, 2016.
SA First Examination Report for Saudi Arabia Application No. 113340401 dated Apr. 28, 2015.
SA First Examination Report for Saudi Arabia Application No. 113340424 dated May 10, 2015.
SA First Examination Report for Saudi Arabia Application No. 113340426 dated May 12, 2015.
SA First Examination Report in Saudi Arabia Application No. 113340400 dated Apr. 13, 2015.
SA Second Examination Report for Saudi Arabia Application No. 113340400 dated Aug. 11, 2015.
Sanchez, et al. “Biological Interactions of Graphene-Family Nanomaterials—An Interdisciplinary Review.” Chem Res Toxicol. 25(1): 15-34 (Jan. 13, 2012).
Sethna et al., “Serum adiponectin levels and ambulatory blood pressure monitoring in pediatric renal transplant recipients,” Transplantation 88(8): 1030-1037 (Oct. 27, 2009).
Sullivan et al., “Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats,” Physiol. Genom. 23(2): 192-205 (Oct. 17, 2005) (available online Aug. 23, 2005).
Swett et al, “Imagining and Sculpting Graphene on the atomic scale” Oak Ridge National Laboratory's (ORNL) Center for Nanophase Materials Sciences (CNMS) Biannual Review. 1 page.
Swett et al, “Supersonic Nanoparticle Interaction with Suspended CVD Graphene”, Microsc. Microanal. 22 (Suppl 3): 1670-1671 (Jul. 25, 2016).
Takata et al., “Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes,” Hypertension 51. 2 (Feb. 2008): 534-9.
Tamborlane et al., “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes” N Engl J Med 359;14: 1464-1476 (Oct. 2, 2008).
Tanugi et al., “Nanoporous Graphene Could Outperform Best Commercial Water Desalination Techniques,” ; ACS 2012; Jun. 25, 2012; Weftec 2012; Sep. 29-Oct. 3.
Totani et al. “Gluten binds cytotoxic compounds generated in heated frying oil.” Journal of oleo science 57.12 (2008): 683-690.
Tsukamoto et al. “Purification, characterization and biological activities of a garlic oliqosaccharide,” Journal of UOEH 30.2 (Jun. 1, 2008): 147-57.
TW Office Action in Taiwanese Application No. 102146079 dated Apr. 14, 2017. 9 Pages.(English translation).
TW Search Report in Taiwanese Application No. 102146079 dated Apr. 14, 2017. 1 page.
UMEA Universitet “Graphene nanoscrolls are formed by decoration of magnetic nanoparticles.” ScienceDaily. Aug. 15, 2013. https://www.sciencedaily.com/releases/2013/08/130815084402.htm (3 pages).
U.S. Notice of Allowance for U.S. Appl. No. 12/868,150 dated Sep. 25, 2012.
U.S. Notice of Allowance for U.S. Appl. No. 13/548,539 dated Aug. 18, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/548,539 dated Jul. 23, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/719,579 dated May 20, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/795,276 dated Oct. 7, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/802,896 dated Apr. 1, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/803,958 dated Aug. 29, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/803,958 dated Jun. 2, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/803,958 dated Sep. 12, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/804,085 dated Jan. 15, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/804,085 dated Mar. 12, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/923,503 dated Oct. 14, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/923,503 dated Oct. 5, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 14/200,195 dated Jul. 5, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 14/200,530 dated Aug. 1, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 14/203,655 dated Dec. 9, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 12/868,150 dated Sep. 25, 2012.
U.S. Notice of Allowance in U.S. Appl. No. 13/795,276 dated Jan. 19, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 13/803,958 dated Aug. 29, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 13/803,958 dated Sep. 12, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated May 5, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/656,580 dated May 8, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/819,273 dated Jun. 9, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 15/099,464 dated Jun. 16, 2017.
U.S. Office Action for U.S. Appl. No. 13/548,539 dated Feb. 6, 2015.
U.S. Office Action for U.S. Appl. No. 13/719,579 dated Jul. 8, 2015.
U.S. Office Action for U.S. Appl. No. 13/719,579 dated May 4, 2016.
U.S. Office Action for U.S. Appl. No. 13/795,276 dated Apr. 22, 2016.
U.S. Office Action for U.S. Appl. No. 13/795,276 dated Oct. 6, 2015.
U.S. Office Action for U.S. Appl. No. 13/802,896 dated Sep. 24, 2014.
U.S. Office Action for U.S. Appl. No. 13/803,958 dated Aug. 11, 2014.
U.S. Office Action for U.S. Appl. No. 13/803,958 dated May 28, 2015.
U.S. Office Action for U.S. Appl. No. 13/803,958 dated Nov. 18, 2015.
U.S. Office Action for U.S. Appl. No. 13/923,503 dated Mar. 22, 2016.
U.S. Office Action for U.S. Appl. No. 14/031,300 dated Jan. 20, 2016.
U.S. Office Action for U.S. Appl. No. 14/031,300 dated Jul. 7, 2015.
U.S. Office Action for U.S. Appl. No. 14/200,195 dated Mar. 21, 2016.
U.S. Office Action for U.S. Appl. No. 14/200,195 dated Nov. 4, 2015.
U.S. Office Action for U.S. Appl. No. 14/200,530 dated Feb. 29, 2016.
U.S. Office Action for U.S. Appl. No. 14/203,655 dated Aug. 10, 2016.
U.S. Office Action for U.S. Appl. No. 14/656,190 dated May 18, 2017.
U.S. Office Action for U.S. Appl. No. 14/656,657 dated Jul. 7, 2017.
U.S. Office Action for U.S. Appl. No. 14/686,452 dated Jun. 9, 2017.
U.S. Office Action for U.S. Appl. No. 14/843,944 dated Jun. 23, 2017.
U.S. Office Action for U.S. Appl. No. 14/856,471 dated May 31, 2017.
U.S. Office Action for U.S. Appl. No. 14/858,741 dated Dec. 1, 2016.
U.S. Office Action for U.S. Appl. No. 15/289,944 dated Feb. 9, 2017.
U.S. Office Action for U.S. Appl. No. 15/336,545 dated Dec. 19, 2016.
U.S. Office Action for U.S. Appl. No. 15/453,441 dated Jun. 5, 2017.
U.S. Office Action in U.S. Appl. No. 14/193,007 dated Apr. 24, 2017.
U.S. Office Action in U.S. Appl. No. 14/656,617 dated Apr. 4, 2017.
U.S. Office Action on U.S. Appl. No. 14/656,335 dated Apr. 25, 2017.
U.S. Office Action on U.S. Appl. No. 15/332,982 dated Jan. 30, 2017.
U.S. Supplemental Notice of Allowance for U.S. Appl. No. 13/795,276 dated Nov. 29, 2016.
Vallon,“Micropuncturing the nephron,” Pflugers Archiv : European journal of physiology 458. 1 (May 2009): 189-201.
Van Der Zande et al. “Large-scale arrays of single-layer graphene resonators.” Nano letters 10.12 (2010): 4869-4873.
Verdonck, P., “Plasma Etching”, in Oficina de Microfabricao: Projeto e Construcao de Ci's MOS, Swart, J.W., Ed., Campinas (Sao Paulo, Brazil): UNICAMP, 2006, ch. 10, p. 9.
Vlassiouk et al. “Large scale atmospheric pressure chemical vapor deposition of graphene.” Carbon 54 (2013): 58-67.
Vriens et al. “Methodological considerations in quantification of oncological FDG PET studies.” European journal of nuclear medicine and molecular imaging 37.7 (2010): 1408-1425.
Wang et al., “Direct Observation of a Long-Lived Single-Atom Catalyst Chiseling Atomic Structures in Graphene,” Nano Lett., 2014, pp. A-F.
Wang et al., “Porous Nanocarbons: Molecular Filtration and Electronics,” Advances in Graphene Science, Edited by Mahmood Aliofkhazraei, (2013) ISBN 978-953-51-1182-5, Publisher: InTech; Chapter 6, pp. 119-160.
Wang et al.,“What is the role of the second “structural ” NADP+-binding site in human glucose 6-phosphate dehydrogenase?,” Protein science a publication of the Protein Society 17. 8 (Aug. 2008): 1403-11.
Wei et al., “Synthesis of N-doped graphene by chemical vapor deposition and its electrical properties”, Nano Lett. 2009 9 1752-58.
Xiaogan Liang et al., Formation of Bandgap and Subbands in Graphene Nanomeshes with Sub-10nm Ribbon Width Fabricated via Nanoimprint Lithography., Nano Letters, Jun. 11, 2010, pp. 2454-2460.
Xie et al., “Fractionation and characterization of biologically-active polysaccharides from Artemisia tripartite,” Phytochemistry 69. 6 (Apr. 2008): 1359-71.
Xie, et al. “Controlled fabrication of high-quality carbon nanoscrolls from monolayer graphene.” Nano letters 9.7 (2009): 2565-2570.
Yagil et al. “Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes” Diabetes 54. 5 (May 2005): 1487-96.
Zan et al. “Interaction of Metals with Suspended Graphene Observed by Transmission Electron Microscopy”, J. Phys. Chem. Lett., Mar. 8, 2012, 3, 953-958.
Zhang et al. “Effect of Chemical Oxidation on the Structure of Single-Walled Carbon Nanotubes”, J. Phys. Chem., Feb. 12, 2003, B 107 3712-8.
Zhang et al. “Method for anisotropic etching of graphite or graphene” Institute of Physics, Chinese Academy of Sciences; PEOP. Rep. China; Mar. 30, 2011.
Zhang et al. “Production of Graphene Sheets by Direct Dispersion with Aromatic Healing Agents”, Small, May 6, 2010, vol. 6, No. 10, 1100-1107.
Zhang et al. “Isolation and activity of an alpha-amylase inhibitor from white kidney beans,” Yao xue xue bao =Acta pharmaceutica Sinica 42. 12 (Dec. 2007): 1282-7.
Zhao, et al. “Efficient preparation of large-area graphene oxide sheets for transparent conductive films.” ACS nano 4.9 (2010): 5245-5252.
Zhou, K., et al., “One-pot preparation of graphene/ Fe304 composites by a solvothermal reaction,” New J. Chem., 2010, 34, 2950.
Zhu et al. “Carbon Nanotubes in Biomedicine and Biosensing”, Carbon Nanotubes-Growth and Applications, InTech, (Aug. 9, 2011) Chapter 6: pp. 135-162. Available from: https://www.intechopen.com/books/carbon-nanotubes-growth-and-applications/carbon-nanotubes-in-biomedicine-and-biosensing.
Ziegelmeier et al. “Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis,” Metabolism: clinical and experimental 57. 10 (Oct. 2008): 1414-21.
Zirk et al. “A refractometry-based glucose analysis of body fluids,” Medical engineering & physics 29. 4 (May 2007): 449-58.
Zyga “Nanoporous Graphene Could Outperform Best Commercial Water Desalination Techniques,” Phys.org., Jun. 22, 2012, Retrieved from http://www.phys.org/pdf259579929.pdf [Last Accessed Dec. 3, 2014] (3 pages).
Dong et al., “Growth of large-sized graphene thin-films by liquid precursor-based chemical vapor deposition under atmospheric pressure,” Carbon 49(11): 3672-3678 (May 2011).
Hong et al., “Graphene multilayers as gates for multi-week sequential release of proteins from surfaces,” NIH-PA Author Manuscript PMC (Jun. 1, 2014), also published in ACS Nano, Jan. 24, 2012; 6(1): 81-88 (first published online Dec. 29, 2011).
Hu et al., “Enabling graphene oxide nanosheets as water separation membranes,” Environmental Science & Technology, 47(8): 3715-3723 (Mar. 14, 2013).
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related international patent application PCT/US2016/027607.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related international patent application PCT/US2016/027616.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027596.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027603.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027610.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027612.
International Search Report and Written Opinion of the International Searching Authority dated Jun. 22, 2016, from related PCT application PCT/US2016/027637.
Kurapati et al., “Graphene oxide based multilayer capsules with unique permeability properties: facile encapsulation of multiple drugs,” Chemical Communication 48: 6013-6015 (Apr. 25, 2012).
Li et al., “3D graphene oxide-polymer hydrogel: near-infrared light-triggered active scaffold for reversible cell capture and on-demand release,” Advanced Materials 25: 6737-6743 (Oct. 7, 2013).
Marquardt et al., “Hybrid materials of platinum nanoparticles and thiol-functionalized graphene derivatives,” Carbon 66: 285-294 (Jan. 2014; first published online Sep. 12, 2013).
Nam et al., “Monodispersed PtCo nanoparticles on hexadecyltrimethylammonium bromide treated graphene as an effective oxygen reduction reaction catalyst for proton exchange membrane fuel cells,” Carbon 50: 3739-3747 (Aug. 2012; first published online Apr. 5, 2012).
Nandamuri et al., “Chemical vapor deposition of graphene films,” Nanotechnology 21(14): 1-4 (Mar. 10, 2010).
Nayini et al., “Synthesis and characterization of functionalized carbon nanotubes with different wetting behaviors and their influence on the wetting properties of carbon nanotubes/polymethylmethacrylate coatings,” Progress in Organic Coatings 77(6): 1007-1014 (Mar. 2014).
Sun et al., “Growth of graphene from solid carbon sources,” Nature 468(7323): 549-552 (Nov. 25, 2010; including corrigendum in Nature 471(7336): 124 (Mar. 2011).
Tang et al., “Highly wrinkled cross-linked graphene oxide membranes for biological and charge-storage applications,” Small 8(3): 423-431 (Feb. 6, 2012; first published online Dec. 13, 2011).
Notice of Allowance for U.S. Appl. No. 14/819,273 dated Oct. 28, 2016.
U.S. Office Action for U.S. Appl. No. 14/193,007 dated Oct. 21, 2016.
U.S. Office Action for U.S. Appl. No. 14/193,007 dated Dec. 21, 2015.
U.S. Office Action for U.S. Appl. No. 14/193,007 dated Jul. 1, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated Jan. 23, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/856,198 dated Feb. 10, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/856,198 dated Mar. 1, 2017.
U.S. Office Action in U.S. Appl. No. 14/609,325 dated Feb. 16, 2017.
U.S. Office Action in U.S. Appl. No. 14/193,007 dated Mar. 23, 2017.
U.S. Office Action in U.S. Appl. No. 14/656,580 dated Feb. 9, 2017.
U.S. Office Action in U.S. Appl. No. 14/843,944 dated Jan. 6, 2017.
U.S. Office Action in U.S. Appl. No. 15/099,464 dated Mar. 10, 2017.
Barreiro et al. “Understanding the catalyst-free transformation of amorphous carbon into graphene by current-induced annealing,” Scientific Reports, 3 (Article 1115): 1-6 (Jan. 2013).
Botari et al., “Graphene healing mechanisms: A theoretical investigation,” Carbon, 99: 302-309 (Apr. 2016) (published online Dec. 2015).
Chen et al., “Defect Scattering in Graphene,” Physical Review Letters, 102: 236805-1-236805-4 (Jun. 2009).
Chen et al., “Self-healing of defected graphene,” Applied Physics Letters, 102(10): 103107-1-103107-5 (Mar. 2013).
Cheng et al., “Ion Transport in Complex Layered Graphene-Based Membranes with Tuneable Interlayer Spacing,” Science Advances, 2(2): e1501272 (9 pages) (Feb. 2016).
Crock et al., “Polymer Nanocomposites with Graphene-Based Hierarchical Fillers as Materials for Multifunctional Water Treatment Membranes,” Water Research, 47(12): 3984-3996 (Aug. 2013) (published online Mar. 2013).
Han et al., “Ultrathin Graphene Nanofiltration Membrane for Water Purification,” Advanced Functional Materials, 23(29): 3693-3700 (Aug. 2013).
International Search Report and Written Opinion in PCT/US2016/027583 dated Jan. 13, 2017.
Written Opinion in PCT/US2016/027590 dated Jan. 6, 2017.
International Search Report and Written Opinion in PCT/US2016/027594 dated Jan. 13, 2017.
International Search Report and Written Opinion in PCT/US2016/027628 dated Jan. 9, 2017.
International Search Report and Written Opinion in PCT/US2016/027631 dated Jan. 13, 2017.
International Search Report and Written Opinion in PCT/US2016/027632 dated Jan. 9, 2017.
Written Opinion in PCT/US2016/052010 dated Dec. 20, 2016.
International Search Report in PCT/US2016/027629 dated Dec. 8, 2016.
International Search Report in PCT/US2016/052007 dated Dec. 27, 2016.
Kjeldsen, T., “Yeast secretory expression of insulin precursors,” Appl Microbiol Biotechnol, 54: 277-286 (May 2000).
Lin et al., “A Direct and Polymer-Free Method for Transferring Graphene Grown by Chemical Vapor Deposition to Any Substrate,” ACSNANO, 8(2): 1784-1791 (Jan. 2014).
Liu et al. “Synthesis of high-quality monolayer and bilayer graphene on copper using chemical vapor deposition,” Carbon, 49(13): 4122-4130 (Nov. 2011) (published online May 2011).
O'Hern et al., “Nanofiltration across defect-sealed nanoporous monolayer graphene,” Nano Letters, 15(5): 3254-3260 (Apr. 2015).
U.S. Corrected Notice of Allowance in U.S. Appl. No. 13/480,569 dated May 26, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 14/610,770 dated Apr. 25, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 14/819,273 dated Dec. 14, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 13/480,569 dated Feb. 27, 2015.
U.S. Office Action in U.S. Appl. No. 13/480,569 dated Jul. 30, 2014.
U.S. Office Action in U.S. Appl. No. 14/856,471 dated Dec. 1, 2016.
U.S. Restriction Requirement in U.S. Appl. No. 14/193,007 dated Jul. 17, 2015.
Wang et al., “Graphene Oxide Membranes with Tunable Permeability due to Embedded Carbon Dots,” Chemical Communications, 50(86): 13089-13092 (Nov. 2014) (published online Sep. 2014).
Xu et al., “Graphene Oxide-TiO2 Composite Filtration Membranes and their Potential Application for Water Purification,” Carbon, 62: 465-471 (Oct. 2013) (published online Jun. 2013).
Zhao et al., “A glucose-responsive controlled release of insulin system based on enzyme multilayers-coated mesoporous silica particles,” Chem. Commun., 47: 9459-9461 (Jun. 2011).
International Search Report dated Dec. 4, 2015, in related international application PCT/US2015/048205.
International Search Report dated Jun. 10, 2015, from related international application PCT/US15/20201.
EPO Extended Search Report for European Application No. 171684883.5 dated Jul. 25, 2017 (8 pages).
EPO Supplementary Search Report for European Application No. 15762019.6 dated Aug. 9, 2017 (16 pages).
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated Sep. 26, 2017. (12 pages).
U.S. Notice of Allowance in U.S. Appl. No. 15/332,982 dated Sep. 21, 2017. (5 pages).
U.S. Office Action in U.S. Appl. No. 15/099,099 dated Oct. 5, 2017 (11 pages).
U.S. Office Action in U.S. Appl. No. 15/099,447 dated Oct. 3, 2017 (21 pages).
Weisen, et al., “Fabrication of nanopores in a graphene sheet with heavy ions: A molecular dynamics study”, Journal of Applied Physics 114, 234304 (2013), pp. 234304-1 to 234304-6.
CN Office Action in Chinese Application No. 201580006829.5 dated Aug. 1, 2017. (English translation) (8 pages).
EP Office Action for European Application No. 15743307.9 dated Aug. 8, 2017. (17 pages).
European Search Report dated Aug. 28, 2017 from related EP application 15743750.0. (7 pages).
International Search Report and Written Opinion dated Aug. 14, 2017 from related PCT application PCT/US2017/031537. (12 pages).
Jiang, L. et al., Design of advanced porous grapheme materials: from grapheme nanomesh to 3D architectures. Nanoscale, Oct. 16, 2013, vol. 6, pp. 1922-1945.
JP Office Action in Japanese Application No. 2015-503405 dated Jun. 28, 2017. (English translation) (6 pages).
JP Office Action in Japanese Application No. 2015-549508 dated Jun. 27, 2017. (English translation) (7 pages).
Li, R.H. “Materials for immunoisolated cell transplantation”. Adv. Drug Deliv. Rev. 33, 87-109 (1998). (23 pages).
Schweitzer, Handbook of Separation Techniques for Chemical Engineers, 1979, McGraw-Hill Book Company, pp. 2-5 to 2-8.
Search Report and Written Opinion dated Aug. 14, 2017 for Singapore Application No. 11201606287V. (10 pages).
Search Report and Written Opinion dated Aug. 22, 2017 for Singapore Application No. 11201607584P. (7 pages).
Sears et al., “Recent Developments in Carbon Nanotube Membranes for Water Purification and Gas Separation” Materials, vol. 3 (Jan. 4, 2010), pp. 127-149.
U.S. Notice of Allowance in U.S. Appl. No. 14/193,007 dated Sep. 6, 2017. (9 pages).
U.S. Notice of Allowance in U.S. Appl. No. 14/656,580 dated Sep. 5, 2017. (8 pages).
U.S. Office Action for U.S. Appl. No. 14/609,325 dated Aug. 25, 2017. (7 pages).
U.S. Office Action for U.S. Appl. No. 15/099,193 dated Jul. 19, 2017. (13 pages).
U.S. Office Action for U.S. Appl. No. 15/289,944 dated Jul. 13, 2017. (18 pages).
U.S. Office Action for U.S. Appl. No. 15/332,982 dated Aug. 18, 2017. (9 pages).
Australian Office Action in Application No. 2013235234 dated Dec. 19, 2017 (5 pages).
Japanese Office Action in Application No. 2017-002652 dated Nov. 24, 2017 (with English translation) (7 pages).
Chu, L., et al., “Porous graphene sandwich/poly(vinylidene fluoride) composites with high dielectric properties,” Composites Science and Technology, 86, (2013), pp. 70-75.
European Extended Search Report in Application No. 15743307.9 dated Nov. 15, 2017 (14 pages).
European Extended Search Report in Application No. 15755350.4 dated Oct. 30, 2017 (9 pages).
European Extended Search Report in Application No. 15762019.6 dated Nov. 20, 2017 (12 pages).
European Extended Search Report in Application No. 15762213.5 dated Oct. 10, 2017 (8 pages).
Gu et al., “One-step synthesis of porous graphene-based hydrogels containing oil droplets for drug delivery”, Royal Society of Chemistry (RSC), vol. 4, No. 7, Jan. 1, 2014, pp. 3211-3218.
Japanese Office Action in Application No. 2015-549508 dated Nov. 7, 2017 (with English translation) (2 pages).
Kim et al., “Selective Gas Transport Through Few-Layered Graphene and Graphene Oxide Membranes”, Science, vol. 342, Oct. 4, 2013, pp. 91-95 (6 total pages).
Singapore Search Report and Written Opinion in Application No. 11201609272T dated Oct. 5, 2017 (11 pages).
U.S. Notice of Allowance in U.S. Appl. No. 15/099,464 dated Nov. 16, 2017 (5 pages).
U.S. Notice of Allowance in U.S. Appl. No. 15/332,982 dated Nov. 1, 2017 (9 pages).
U.S. Office Action in U.S. Appl. No. 14/707,808 dated Nov. 6, 2017 (27 pages).
U.S. Office Action in U.S. Appl. No. 15/099,193 dated Dec. 28, 2017 (25 pages).
U.S. Office Action in U.S. Appl. No. 15/099,304 dated Nov. 24, 2017 (23 pages).
Wang, M., et al., “Interleaved Porous Laminate Composed of Reduced Graphene Oxide Sheets and Carbon Black Spacers by In-Situ Electrophoretic Deposition,” The Royal Society of Chemistry (2014), pp. 1-3.
Wimalasiri, Y., et al., “Carbon nanotube/graphene composite for enhanced capacitive deionization performance,” Carbon 59 (2013), pp. 464-471.
Bose et al.,“Microfabricated immune-isolating devices for transplanting therapeutic cells in vivo”, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Undated (1 page).
Indian Office Action for Appl. Ser. No. 7731/DELNP/2014 dated Jul. 26, 2018 (6 pages).
Japanese Office Action for Appl. Ser. No. 2017-002652 dated Jul. 3, 2018 (8 pages).
Linnert, “Welding Metallurgy—Carbon and Alloy Steels”, vol. I—Fundamentals (4th Edition), Chapter 2—The Structure of Metals, GML Publications, American Welding Society (AWS), Year: 1994, pp. 17-74. Retrieved from app.knovel.com/hotlink/pdf/id:kt0095RCL3/welding-metallurgy-carbon/structure-metals.
U.S. Final Office Action for U.S. Appl. No. 14/707,808 dated Jun. 27, 2018 (28 pages).
U.S. Final Office Action for U.S. Appl. No. 15/099,482 dated Aug. 27, 2018 (10 pages).
U.S. Non-Final Office Action for U.S. Appl. No. 15/099,239 dated Jul. 12, 2018 (31 pages).
U.S. Non-Final Office Action for U.S. Appl. No. 15/099,304 dated Aug. 27, 2018 (22 pages).
U.S. Notice of Allowance for U.S. Appl. No. 15/099,420 dated Aug. 8, 2018 (8 pages).
Vatanpour et al., “Fabrication and characterization of novel antifouling nanofiltration membrane prepared from oxidized multiwalled carbon nanotube/polyethersulfone nanocomposite”, Journal of Membrane Science, vol. 375, Elsevier, Apr. 6, 2011, pp. 284-294.
Zhang et al., “Synergetic effects of oxidized carbon nanotubes and graphene oxide on fouling control and anti-fouling mechanism of polyvinylidene fluoride ultrafiltration membranes”, Journal of Membrane Science, vol. 448, Elsevier, Aug. 7, 2013, pp. 81-92.
European Extended Search Report in Application No. 15837617.8 dated Mar. 22, 2018 (9 pages).
Singapore Written Opinion for Appl. Ser. No. 11201607584P dated Jun. 8, 2018 (7 pages).
U.S. Non-Final Office Action for U.S. Appl. No. 15/099,410 dated Jun. 13, 2018 (15 pages).
U.S. Notice of Allowance for U.S. Appl. No. 15/453,441 dated Jun. 12, 2018 (8 pages).
U.S. Office Action for U.S. Appl. No. 15/099,289 dated Jun. 7, 2018 (16 pages).
US Final Office Action for U.S. Appl. 14/609,325 dated Sep. 12, 2018 (8 pages).
US Final Office Action for U.S. Appl. No. 15/099,289 dated Oct. 15, 2018 (14 pages).
US Non-Final Office Action for U.S. Appl. No. 14/656,657 dated Oct. 10, 2018 (6 pages).
US Non-Final Office Action for U.S. Appl. No. 14/707,808 dated Nov. 15, 2018 (34 pages).
US Non-Final Office Action for U.S. Appl. No. 15/099,099 dated Sep. 27, 2018 (13 pages).
US Non-Final Office Action for U.S. Appl. No. 15/099,269 dated Oct. 5, 2018 (11 pages).
US Non-Final Office Action for U.S. Appl. No. 15/099,276 dated Nov. 1, 2018 (13 pages).
Related Publications (1)
Number Date Country
20170299537 A1 Oct 2017 US